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ABSTRACT 
 
Surface exposed proteins of Streptococcus agalactiae (GBS) may be used in 
serotyping and may have a potential role as vaccine candidates. The proteins 
R3 and the recently discovered Z1 and Z2 were found to be important 
markers in GBS from Zimbabwe. However, their prevalence in most 
geographical areas, and the genes encoding these proteins have so far not 
been identified. Therefore, the aim of this work was to identify candidate 
genes (CGs) for the R3, Z1 and Z2 GBS surface exposed proteins in GBS.  
Two GBS strains from Zimbabwe, GMFR293 and CMFR30, found to 
express R3, Z1 and Z2, and Z1, respectively, were genome sequenced. 
CMFR30 was sequenced on a Pacific Biosciences instrument and assembled 
to a complete genome. GMFR293 was sequenced by Roche 454 pyro 
sequencing, which was combined with optical mapping for assembly to a 
complete genome. RAST was used for in silico gene prediction and 
functional annotation for each genome, for comparison of predicted coding 
sequences (CDSs) and for comparison with four reference genomes of R3, 
Z1 and Z2 negative strains. The CDSs were analysed by various 
bioinformatics tools to identify candidate genes. CDSs were analysed to 
estimate the molecular weight (MW) of the encoded protein and to predict the 
potential surface exposition. Based on previous published characteristics of 
the R3, Z1 and Z2 proteins, CGs were chosen among CDSs encoding 
proteins of a MW higher than 50 kDa, which had a functional annotation as 
membrane or surface associated protein or as hypothetical protein (HP) 
predicted to be potentially surface exposed.  
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GBS strain GMFR293 comprised 2,037,090 bp and CMFR30 2,062,772 bp, 
respectively. A total of 2023 CDSs were predicted in GMFR293 and 2060 in 
CMFR30. Around 80% of all CDSs had a putative assigned function. Unique 
genes were identified when they were compared with the other GBS strains. 
26% of the CDSs from both genomes were predicted as TM proteins. From 
these, 113 CDSs from strain GMFR293 had a MW >50 kDa: 21 harboured a 
signal peptide, eight and four had an LPxTG and/or YSIRK signal, 
respectively, and 14 were identified as lipoproteins. In comparison, of 70 
CDSs predicted as TMs in CMFR30 that had a MW >50 kDa, nine 
harboured a signal peptide, seven and one had an LPxTG and/or YSIRK 
signal, respectively, and 6 were identified as lipoproteins. Finally, 51 CDSs 
were chosen as CGs for R3, Z1 and Z2 in the GMFR293 genome, and 32 
CDSs were chosen as CGs for Z1 in the GMFR30 genome. Among them 
were CDSs annotated as hypothetical protein, with putative function and 
some with predicted function. The CGs identified by in silico analyses in this 
study need to be further tested in experimental analyses, before. This work 
demonstrates that identification of candidate genes for the surface exposed 
proteins R3, Z1 and Z2 can be done by comprehensive in silico 
characterization of selected reference genomes.  
Among the CGs for R3 was a hypothetical protein of 105kDa which showed 
97% similarity with the R5 (BPS) protein encoded by the sar5 gene 
published in NCBI. To test the hypothesis whether R5 may be similar or 
identical to R5, the sar5 gene was coned in E. coli LB21 expression of R3 
protein and was thereafter tested by immunological methods. However, the 
observation that transformants were negative for expression of R3 by 
immunofluorescence testing may indicate that R3 and R5 are different 
proteins. However, there may be other possible explanations for these 
results, which need to be evaluated in further experiments.  
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In this study we have assembled two GBS strains to near complete genomes, 
and done a thorough in silico characterization of the two GBS genomes with 
prioritization of potential candidate genes for the surface associated proteins 
R3, Z1 and Z2. Final identification of the genes encoding these proteins 
depend on either that more information about the physical and phenotypic 
characteristics of these proteins becomes available in the future, or 
experimental analysis of expression of the proteins in overexpression or gene 
knockout experiments. This work describes the first attempt to identify CGs 
for these three GBS proteins. 
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1 INTRODUCTION 
 
Streptococcus agalactiae (Group B streptococcus, GBS) is an important 
human and animal pathogen. In humans, it is the leading cause worldwide of 
diseases such as neonatal pneumonia, sepsis and meningitis. It is also a cause 
of morbidity among pregnant women, and was recently found to be 
pathogenic in immunocompromised adults
1; 2
. GBS strains are classified into 
ten different serotypes known so far (type Ia, Ib and II through IX) based on 
differences in capsular polysaccharide (CPS) 
3-5
. In addition to the CPS, the 
proteins exposed on the bacterial cell surface are considered as important 
markers in typing of GBS. Also, several studies suggest that surface proteins 
play a major role in GBS binding during the invasion of human mucosal 
surfaces. Both the capsular antigen and the cell surface proteins are 
important targets of protective antibodies and as vaccine candidates
2; 4; 6
. 
GBS express several surface proteins. There are some highly conserved and 
others are highly associated with speciﬁc serotypes7; 8. The distribution of 
serotypes and surface protein vary with geographical region, ethnic origin 
and the virulence of clinical isolates
5; 9
. Therefore, effective vaccines based 
on strain variable surface antigens should preferably contain more than a 
single antigen in order to confer protection against predominant circulating 
serotypes
6
. 
These strain variable proteins include: the c proteins (α and β), the R proteins 
(R1 through R5) and the most recently described Z proteins (Z1 and Z2)
10; 11
. 
Many of the genes encoding surface proteins have been identified
9
. 
However, the genes coding R3 and Z proteins are unknown so far. The 
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identification of candidate genes for R3 and Z through in silico methods is 
the main aim of this study.  
On the other hand, in a previous study on surface protein serotype markers in 
a GBS strain collection from Zimbabwe, it was observed that strains that 
expressed R3, almost always expressed R5 surface protein (97%)
5; 11
. Since 
the sequence of the gene encoding the R5 surface protein (sar5) has been 
published and is available in the NCBI data base, experiments using cloning 
and transformation of sar5 could help to elucidate if this gene encodes R3 or 
not and thereby clarify if R3 and R5 are identical or distinct antigens.  
To date, there are seven complete whole genome sequences and more than 
two hundred incomplete genome sequences of GBS strains, available as 
contigs, in the NCBI database (www.ncbi.nlm.nih.gov). That type of 
information available in the genomic databases, together with information 
from studies on serotype surface protein markers on GBS strains, 
bioinformatics software,  recombinant DNA techniques and an accurate 
prioritization of candidate genes, constitutes keys steps in accelerating the 
discovery of gene functions of this important pathogen. This type of 
knowledge may also be of importance for the understanding of pathogenesis 
and for vaccines development. 
 
1.1. The genus Streptococcus 
 
The genus Streptococcus is a diverse group of Gram-positive bacteria with a 
considerable importance in medicine and in industry
12
. Various streptococci 
are important in several ecosystems, as part of the normal microbial flora of 
4 
 
animals and humans. However, they are also one of the most invasive groups 
of bacteria, being identified as causes of many infections in humans and 
animals. For instance, some species considered to be common cause of 
infections include: S. pneumoniae, S. pyogenes, S. suis, S. dysgalactiae, S. 
agalactiae, S. mutans and S. viridans
13; 14
. 
1.1.1 Classification and features 
Taxonomically, the genus Streptococcus is classified as: Bacteria Kingdom, 
Phylum Firmicutes, Class Bacilli, Order Lactobacillales and Family 
Streptococcaceae. This Family includes the genera: Enterococcus, 
Lactococcus and Streptococcus. Phenotyphically, Streptococcus strains are 
Gram-positive cocci, less than 2 µm in diameter, and usually arranged in 
pairs or chains of varying lengths. They do not form spores, they are 
facultative anaerobic, catalase negative and have complex nutritional 
requirements
15; 16
.  
Streptococci are classified on the basis of colony morphology, hemolysis, 
biochemical reactions, and beta haemolytic streptococci mainly by serologic 
specificity. They are divided into three groups by the type of hemolysis on 
blood agar: β-hemolytic (clear, complete lysis of red cells), α hemolytic 
(incomplete, green hemolysis), and γ hemolytic (no hemolysis). The 
serologic grouping is based on ‘’Lancefield grouping’’, which is based on 
antigenic differences in cell wall carbohydrates (designed by a upper-case 
letter of the alphabet - groups A to V), in the cell wall pili-associated protein, 
and in the polysaccharide capsule in group B streptococci 
13; 16
.  
Currently, there are more than 100 species within the Streptococcus genus 
14
. 
Most of them are grouped in six ‘’species groups’’: Pyogenic, Mitis, 
Salivarius, Bovis, Anginosus and Mutans. However, some of the non-
pyogenic streptococci (Mitis, Anginosus and Salivarius) often referred to as 
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viridans streptococci, have been resistant to satisfactory classification, which 
is reflected in frequently changing nomenclature and significant problems of 
identification by phenotypic analysis and by sequencing of 16S rRNA 
genes
15
. 
1.2. Group B Streptococccus (GBS): Streptococcus 
agalactiae 
 
Streptococcus agalactiae belongs to the pyogenic group and constitutes the 
Lancefield’s group B Streptococci (GBS)16. This Gram-positive encapsulated 
bacterium exhibits various types of haemolysis on blood agar, mostly β-
hemolysis, but 1-3% do not cause any haemolysis
17
.  
The name GBS comes from the polysaccharide type anchored to their cell 
wall; the group B specific carbohydrate (GBC), and their serotype comes 
from their capsular polysaccharide antigen (CPA), which defines the ten 
different serotypes known today (Ia, Ib, II, III, IV, V, VI, VII, VIII and IX)
18
.  
1.2.1. Epidemiology and burden of GBS disease 
GBS can be found as a commensal bacterium or as an opportunistic pathogen 
in humans and in animals (ruminants
19
 , dogs, horses, guinea pigs
20
, camel
21
, 
cattle
22
  and fish
23
). It is the leading cause of neonatal sepsis worldwide. In 
humans, the risk populations are: neonates, pregnant women and non-
pregnant adults. In neonates GBS may cause pneumonia, sepsis or 
meningitis. GBS also causes morbidity among pregnant women, and it is 
also pathogenic in immunocompromised adults and in the elderly, where an 
increase in the number of cases have been reported from several countries
1; 2; 
18
. The prevalence of GBS and serotype distribution has changed over time 
and between regions, both within and between countries
18; 24
.   
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Neonatal GBS disease 
New-borns are the population most affected by the impact of GBS disease in 
terms of severity and incidence. It takes place in the neonatal period up to the 
first 90 days of life. Neonatal GBS disease has been divided in two groups: 
early onset disease (EOD) and late onset disease (LOD)
25
. 
Early onset GBS disease (EOD) accounts to approximately 60-70 % of all 
neonatal GBS disease. It is defined as disease which starts within the first six days 
of life (0-6 days). EOD infection is usually caused by transmission of GBS from the 
mother either before or during birth. About 15% to 30% of pregnant women are 
colonized asymptomatically with GBS in the gastrointestinal and/or genital tracts
26; 
27
. Infection takes place via vertical transmission, between the infant and a mother 
who is GBS carrier during the pregnancy.  Around 50% of babies of colonized 
mothers become colonized, but only 0.5-2 per 1000 live births develop EOD due to 
GBS infection
27
. Maternal intrapartum GBS colonization is the primary risk factor 
for early-onset disease in infants. A classic prospective cohort study conducted 
during the 1980s revealed that pregnant women with GBS colonization were >29 
times more likely than pregnant women with negative prenatal cultures to deliver 
infants with early-onset GBS disease
28
. In addition to maternal colonization, there 
are others factors associated with an increased risk of neonatal colonization, these 
include: male sex, black race, prolonged rupture of membranes, prematurity, low 
levels of maternal anti-GBS antibodies and intrapartum fever
25; 29
. The disease 
shows rapid progression, with signs like respiratory distress, apnea, or other signs of 
sepsis, which are often evident at birth or within the first 12 hours of life. It could 
present as pneumonia, sepsis or meningitis, or a combination of them
25
. 
Late onset GBS disease (LOD) is defined as infection occurring later in 
infancy from 7 to 90 days. It is caused predominantly by strains of serotype 
III. In this case, the infection can be acquired from the mother (perinatally) 
or from environmental sources (nosocomially or from community sources). 
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The two most common clinical manifestations of LOD are meningitis and 
bacteraemia. The mortality rate for the disease is significantly lower (2-6%) 
than the rate of EOD, but the morbidity is high
18
. 
The burden of GBS disease in new-borns  
A review of the current burden of GBS disease was published by Edmonds et 
al. in 2012
29
.  The study reported data collected after year 2000 from several 
countries around the world. In this study, the following were estimated: (a) 
the incidence of GBS invasive disease and case fatality in infants aged 0–89 
days, (b) the incidence of EOD and LOD and (c) the distribution of GBS 
serotypes in invasive disease specimens.  
There was substantial heterogeneity among the studies. Differences in 
incidence were observed both between and within geographic regions
24
. The 
overall incidence was of 0.53 cases per 1000 live births (range 0.44 - 0.62) in 
the European region, 0.67 (0.54 - 0.80) in the Americas and 0.15 (0.03 - 
0.07) in Australasia. The mean case fatality rate was 9.6% (7.5 - 11.8). The 
incidence of EOD was 0.43 per 1000 live births (0.37-0.49) and the case 
fatality rate of EOD (6.2–18.3) were two-times higher than LOD29. 
The most prevalent serotype in all regions was CPS type III (48.9%) 
followed by types Ia (22.9%), V (9.1%), Ib (7.0%) and II (6.2%)
29
. The 
distribution of CPS types seems to be similar in Africa, western Paciﬁc, 
Europe, the Americas, and the eastern Mediterranean regions, and it has not 
changed over the past 30 years
18
. 
Prevention 
To prevent GBS diseases in neonates, screening based strategies and 
intrapartum antibiotic prophylaxis has been implemented in several 
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European countries and in the USA. Other strategy which is used by several 
countries including Norway is a risk based strategy where antibiotic 
treatment is given only in the presence of specific risk factors for GBS 
disease. These strategies have been shown to reduce the incidence of EOD, 
but not LOD, and had only a limited impact on the incidence of GBS disease 
in pregnant women. Therefore, a better method of protecting infants is 
required. Several different GBS carbohydrates and antigenic proteins have 
been considered candidates for potential vaccines. However, currently there 
is not a GBS vaccine available, although vaccination is an attractive 
preventative strategy. The current status of the GBS antigens that have been 
studied as potential vaccine candidates are summarized in  the table 1-1
30
. 
 
Table 1-1. GBS antigens with potential as vaccine candidates31; 32. 
Antigen Virulence factor Preclinical studies Clinical studies 
Carbohydrates  
Group B antigen No Yes No 
Ia CPS Yes Yes Phase 1 and 2 
Ib CPS Yes Yes Phase 1 and 2 
II CPS Yes Yes Phase 1 and 2 
III CPS Yes Yes Phase 1 and 2 
V CPS Yes Yes Phase 1 
VI CPS Yes Yes No 
VIII CPS Yes Yes No 
Proteins 
C proteins 
Alpha Yes Yes No 
Betha ? Yes No 
Epsilon ? No No 
Rib ? Yes No 
R proteins ? No No 
C5a peptidase ? Yes No 
Sip ? Yes No 
LrrG Yes Yes No 
Pili Yes Yes No 
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GBS disease in pregnant and post-partum woman 
GBS has been reported as a pathogen in pregnant woman, who has a higher 
estimated relative risk for GBS disease (5.0, range 2.9 - 8.7) compared with 
non-pregnant women
33
. Maternal colonisation of GBS can vary depending 
on ethnicity and geographical distribution. The serotypes causing maternal 
GBS disease have been similar to those that cause EOD
18
.  
GBS cause different types of disease in mother and child.  During pregnancy 
GBS infection can cause miscarriage, intra-amniotic and urinary tract 
infection. In the post-partum period a mother colonized with GBS could 
develop invasive disease, endometritis or chorioamnionitis (inflammation of 
the fetal membranes). Most pregnancy-associated disease of the mother 
occurs in the postpartum period
18; 33
. The recognition and identification of 
maternal GBS colonisation has been the key factor of preventive strategies of 
perinatal GBS disease. 
GBS Disease in non-pregnant adults  
GBS in non-pregnant adults cause diseases as: skin, and/or soft tissues 
infections, bacteraemia, pneumonia and less often problems as osteomyelitis, 
meningitis and endocarditis associated with considerable morbidity and 
mortality
18; 34
. The risk factors that have been shown to be related with 
disease in non- pregnant adults are: older age, diabetes mellitus, 
cardiovascular diseases, heart failure, history of cancer, alcoholism, obesity 
and liver and renal insufficiency.  
The case fatality rate is markedly higher among adults than among new-
borns. However, compared to neonatal disease, the epidemiology in non-
pregnant adults has been less studied. The rate of invasive disease is 
approximately 7 cases per 100,000 non-pregnant adults. The risk of death is 
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lower among younger adults, and adults who do not have underlying medical 
conditions. The source of infection for adults is unknown
35
.  
1.2.2. Virulence factors of Group B streptococcus 
The virulence of a microorganism is deﬁned as the degree of pathogenicity 
or the relative capability of a microbe to cause host damage. GBS encodes a 
variety of virulence factors that facilitate its ability to invade the host, cause 
disease, and evade host defence mechanisms. Some of these virulence factors 
have been identified and characterized, and include: the cell wall 
carbohydrate antigen (group B antigen and capsular polysaccharides), toxins 
(β-hemolysin/cytolysin (β-H/C) and CAMP factor), pili and several surface 
proteins
36; 37
. 
Cell wall carbohydrates antigens:  The two major factors by which this 
pathogen evades the host defence mechanism are the group B-specific 
antigen and the capsular polysaccharides.  
Group B specific antigen is common to all GBS strains. It is composed of 
four different oligosaccharides: rhamnose, galactose, N-acetylglucosamine, 
and glucitol in a highly conserved structural arrangement
38
. 
Capsular polysaccharides confer serotype specificity and are considered as 
highly important GBS virulence factors. Currently, there are 10 different 
GBS serotypes (Ia, Ib, II to IX), each of them antigenically and structurally 
unique. They are complex carbohydrates composed of approximately 150 
repeating oligosaccharide subunits and each subunit contains a mono-, di-, or 
disaccharide side chain terminating in an N-acetylneuraminic acid (sialic 
acid) residue. The ten serotypes are different by their arrangements of 
monosaccharides within the oligosaccharide repeat units
39
. 
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The cell wall anchored polysaccharide capsule is recognized as virulence 
factor because it inhibits the deposition of alternative complement pathway 
factor C3b on the surface of the bacterium, causing decreased phagocytosis 
by macrophages and neutrophils in the absence of serotype-specific 
antibody
40
. 
Pore-forming toxins: GBS encodes at least two pore forming toxins: the β-
hemolysin/cytolysin (β-H/C) and the CAMP factor. These promote the entry 
of the pathogen into the host cells, which facilitate their survival and 
dissemination
37
.  
β-hemolysin/cytolysin (β-H/C) is encoded by the cylE gene of GBS and its 
expression is associated with the production of an orange pigment. Invasive 
GBS infections are almost exclusively caused by β -hemolytic strains. The β-
H/C is toxic for many eukaryotic cells and it has a strong influence on the 
intracellular survival of the bacteria inside the host. In addition, the orange 
pigmentation is related to the protection of GBS against the toxic effects of 
reactive oxygen species (ROS), generated by the oxidative mechanism of 
phagocytic killing by macrophages
41; 42
. 
CAMP factor is another secreted protein with pore-forming properties that 
has been observed to oligomerize and form discrete pores on susceptible 
target membranes. Experiments have shown an increased mortality when 
injection of purified CAMP factor is inoculated in rabbits and mice. 
However, its role in GBS pathogenesis remains controversial since some 
authors have observed that deleting the CAMP factor encoding gene (cfb) in 
a GBS strain does not result in attenuation of systemic virulence potential of 
this strain
43
. A suggested explanation for that observation is that the CAMP 
factor may be nonessential for GBS pathogenesis. Given their pore-forming 
abilities, it is also likely that β-H/C may play a compensatory role for the 
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absence of CAMP factor during infection. So, CAMP factor may only be 
essential for GBS pathogenesis in host niches where β-H/C activity is 
diminished
37
.  
Pili are small cell-surface exposed appendages that have been discovered as 
important virulence factors in GBS, as well as promising vaccine candidates. 
Pili mediate GBS resistance to antimicrobial peptides (AMPs), facilitate 
adherence and attachment of this pathogen to host cells, promote entry into 
the central nervous system and enhance biofilm formation and resistance to 
phagocyte killing.  
In GBS there are three pathogenicity islands encoding pilin proteins: Pilus 
Island-1 (PI-1), Pilus Island-2a (PI-2a) and Pilus Island-2b (PI-2b). Pili are 
high molecular weight structures made of two subunits:  the major backbone 
protein (BP) that is distributed along the pilus structure, and two ancillary 
proteins (AP), a major (AP1) and a minor (AP2) that are needed for pilus 
assembly. The pilus 2a backbone protein (BP-2a) is one of the most 
structurally and functionally characterized components of a potential vaccine 
formulation against GBS
37; 44
. 
Surface proteins consist of diverse groups of proteins that mediate bacteria-
host receptor interactions. They act as adhesins and may also be involved in 
the evasion of the immune system. So far, 27 main surface proteins have 
been identified in GBS. Some of these are anchored to the bacterial 
membrane while others are just surface expressed proteins
14
. Some surface 
proteins are highly conserved and present in all GBS strains (see table 1-2) 
while others are highly associated with speciﬁc serotypes (see table 1-3)7. In 
addition, the proteins exhibit size variation between strains, depending on the 
number of nucleotide repeats in the corresponding genes
45
. 
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Table 1-2. GBS Surface proteins expressed in most of the GBS strains  
 
 
 
 
Protein Gene Approx. 
MW (kDa) 
Function and characteristics Ref. 
Surface immunogenic protein 
(Sip)  
Sip 45.5 kDa Unknown function.  46; 47 
C5a peptidase A (ScpA) ScpB 120 kDa Promotes resistance to phagocytosis Surface exposed protein.  48 
C5a peptidase B (ScpB ) ScpB 140 kDa Promotes resistance to phagocytosis Surface exposed protein.  48 
Laminin binding surface 
protein (Lmb)   
Lmb 34 kDa Surface exposed lipoprotein. Role in colonization and invasion. 
Gene is located on a putative composite transposon. 
4 
Fibrinogen-binding protein  
( FbsA) 
fbsA 110kDa Binds to human fibrinogen and is involved in the adhesion of 
GBS to human cells. 
49 
Serine-rich protein (Srr-1) srr-1 144 kDa Promotes colonization by enhancing adhesion.  50 
Serine-rich protein (Srr-2) srr-2 132 kDa Unknown function. Associated to CPS III. Highly virulent 
variants have been associated with the gene srr-2. 
51 
Cell surface associated 
protein  (CspA) 
cspA 7.3 kDa Cleaves human fibrinogen and selected chemotaxins. Surface 
associated protein.  
52 
Hyaluronate lyase  (HylB)  hylB 121.2 kDa Associated with cell invasion. 53 
Sortase A (SrtA) srtA 27.1 kDa Required for adhesion to epithelial cells. 48 
14 
 
Strain variable proteins are important GBS serotype markers. Among these 
strain variable proteins are included: the C protein (α and β subunits), the R 
proteins (R1 through R5), the alpha-like proteins and the most recently 
described Z proteins (Z1 and Z2)
10; 11
. These proteins are highly complex 
immunologically, and have sites with different antigenic specificities, and 
sites which seem to be immunologically identical
54
. Many of the genes 
encoding surface proteins have been identified
9
. However, the genes coding 
R3 and Z proteins have not been identified so far (see table 1-3). The 
characterization of their structures may advance the understanding of some 
details of the pathogenesis and the vaccines against GBS diseases.  
 
Table 1-3. Strain variable surface proteins of GBS 
Surface 
Protein 
Gene GenBank 
Number 
Approx. MW 
(kDa) 
CPS serotype  
association 
c protein     
Cα bca55 M97256 62.5 to 167 kDa Ia, Ib, II, IX2; 5; 6 
Cβ bac56  130 kDa Ia, Ib, II, IX5; 6 
R proteins     
R1/ Alp2 alp257 AF208158 74.7 kDa Ia, III, V8; 45 
R2/ Alp3 alp357 AF245663 77.7 - 95.1 kDa V, VII, VIII45 
R3 unknown - 140 kDa Ia, II, III,V5; 7; 10 
R4/ Rib rib46 U583333 65-123 kDa II, III, V, VIII8; 9; 45 
R5 sar56 AJ133114 105kDa V 24 
Other alp-like proteins    
Alp1/Epsilon alp1 U33554 23.98 - 43 kDa Evenly distributed and 
prevalent in bovine 
strains45 
Alp 4 alp4 AJ488912 38.63 kDa *NT strains45 
Z proteins     
Z1 unknown - >250 kDa V 5 
Z2 unknown - 135 kDa V 11 
 
*No typeable 
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Alpha-like protein family 
Several of the major GBS surface proteins belong to a large protein family 
called the alp-like proteins (Alp). GBS strains usually contain at least one of 
the genes encoding Alp-like proteins
58
. Such genes are mosaic allelic 
structures generated by a recombination of modules at the same 
chromosomal locus, resulting in sharing of epitopes and immunological cross 
reactivity between different proteins belonging to this group
45
.  Among the 
alp-like protein family and its encoding genes present in GBS are: Cα protein 
(bca), Alp1 (epsilon/alp1), Alp2 (alp2), Alp3 (alp3), Alp4 and R4/Rib (rib)
4
.  
Alp-like proteins are high molecular mass proteins. The biological 
function(s) of the Alp family of proteins remains unclear. However, it is 
known that deletion an Alp-like gene may cause attenuated virulence of the 
GBS strain (53). All Alp family proteins are constructed in a similar manner: 
1) a signal peptide of ~50 amino acids (aa); 2) N terminus composed of ~180 
aa; 3) C terminus with a variable number of identical and tandemly arranged 
repeats, each composed of ~80 aa; 4) C-terminal end of 40-50 aa and with a 
cell wall anchoring motif. Variable number of repeats results in variation in 
molecular mass of the proteins.  Both the N terminus and the repeat region 
possess immunogenic domains of different immunological specificities. The 
level of sequence homology between the N and C termini of different Alps 
seems to determine the level of immunological cross-reactivity or uniqueness 
of these domains, for instance if domains are protein-specific. 
C proteins 
The C protein was the first surface protein which was identified in GBS. It is 
composed of α and β protein subunits. A GBS strain can express one of them 
or both
2
. The C alpha protein which is trypsin resistant has been found to be 
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present in many clinical GBS isolates, and has also been found in other 
Gram-positive organisms
4
. The calculated mass for the protein is 103 kDa.  It 
consists of an a C-terminal domain (45 amino acids), containing an LPXTG 
peptidoglycan-anchoring motif, and an N-terminal domain (170 amino acids) 
followed by a variable number of tandem repeats (82 amino acids 
each)
46
.The C Beta protein which is trypsin sensitive, is unrelated to the 
other component of the c antigen
4
. It is known to bind different components 
of the immune system, which suggest that Beta C protein plays a role in 
virulence. However, it is unknown if it is a virulence factor. The genes 
encoding the two components of the C protein are located in the same part of 
the GBS chromosome, but they are not closely linked
4
. 
R proteins 
The R proteins of GBS are cell surface proteins that are resistant to certain 
proteases. They were described first in group A Streptococcus, but were later 
found to be present in several different B-haemolytic Streptococci (A, B, C, 
F, G, and L). However, they are not produced by all the strains
59
.  Until now, 
five distinct species of R proteins have been identified in GBS, according to 
their immunoprecipitation reactions in agarose; R1, R2, R3, R4 and R5, 
However, some of the R proteins are alp-like proteins; for instance, R4 
protein has been found to be identical to protein Rib. 
In general, studies regarding serotype markers of GBS strain collections 
from different geographical locations have shown that the distribution of 
serotypes and surface protein change with geographical region and the ethnic 
origin
5; 9
. These proteins have been subject to scientific research with the aim 
of create vaccines against GBS. An effective vaccines based on strain 
variable surface antigens should preferably contain more than a single 
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antigen in order to confer protection against predominant circulating 
serotypes
6
. 
1.2.3. R3, Zs and R5 Surface proteins association 
Among the less well studied GBS membrane proteins are R3, R5 and the 
most recently described Z proteins Z1 and Z2. These proteins were found to 
be present in a high proportion of GBS strains from pregnant women from 
Zimbabwe, but less common in clinical isolates from Norway. However, 
knowledge about the occurrence of these markers in other geographical 
locations is missing.  
Among these proteins, R5 is the only one where the corresponding gene has 
been sequenced.  Its relationship to the R3 and the Z proteins (which usually 
are present in the same strains) has been not established. The genes encoding 
the Z and R3 proteins have  not yet been identified and sequenced, but their 
expression and some features has been determined by several antibody-based 
methods such as immunofluorescence
60
, whole cell-based ELISA  and by 
Western blotting
5
.   
R5 surface protein: Initially called BPS (group B protective surface 
protein), the R5 protein was described in 2002 as a new R-like protein.  This 
protein was identified from the GBS strain Compton R (ATCC9828/ 
Compton 2560/Prague 2560) which was previously typed as R3 and R4 
positive, using a polyclonal antiserum raised against the R protein fraction of 
this strain to screen a lambda Zap library. DNA sequence analysis showed 
that R5 belongs to a family of the GBS surface proteins with repetitive 
structures. It is formed by 979 amino acids and it contains two identical 
repeats of 76 amino acids separated by a 101 amino acids spacer in the C- 
terminal region. The protein has a signal  
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sequence and a membrane anchor region typical of a Gram positive surface 
protein. Its surface location was confirmed by immunogold electron 
microscopy using BPS specific antiserum, and it was identified as a unique 
protein separate from R3 and R4 by immunoprecipitation in agarose gels. R5 
did not show cross-reaction with the R1 and R4 and appeared to be different 
from R3, the other surface proteins present in the Compton R strain
6
.   
Although R5 was found to be different from R3 in the initial study, later 
studies done on these proteins have indicated that they are highly related.  A 
study on different serosubtype protein markers detected in GBS strains from 
Zimbabwe, showed that GBS isolates which were positive for R3 expression 
were almost always R5 gene positive (97%) as well
24
. In the same study, 
variable R3 antigen expression was found when some GBS strains were 
negative for the R3 protein expression in whole cell based ELISA but in a 
posterior absorption test, R3 expression was confirmed
24
.  This results are 
agree with the previous knowledge about  GBS genes may not always be 
expressed, or expressed in quantities insufficient for detection of the gene 
product
61
.  
An attempt to identify the R3 protein sequences from R3 positive GBS 
strains by mass spectrometry in 2010 resulted in a.a-sequences consistent 
with R5 protein sequences (unpublished results).  This result, together with 
the inclination of R3 expression and R5 gene possession to occur together 
made it possible that the encoding genes and gene products, R3 and R5, 
could be identical. Elucidation of this possibility was one of the goals of the 
present study. 
R3 surface protein: The R3 protein was described in 1972 as one of the 
members of the R proteins found in GBS
62
. Initially called P protein and then 
called R3 protein, it has been characterized by immunological methods.  In 
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spite of its expression has been known for a long time, it has been not 
sequenced until now, perhaps because R3 has been considered of low 
prevalence. However, the R3 surface protein prevalence in GBS carrier 
strains has been found variable depending on the geographical site of the 
study. It was showed in a study comparing GBS strains collections from 
Zimbabwe and Norway that R3 expression occurred with a much higher 
frequency in Zimbabwe than in Norwegian isolates
24
.  
From the immunological experiments it is known that the R3 protein is a 
high molecular mass protein in the range of 130-140 kDa. It is a trypsin 
resistant protein that forms a ladder-like banding patterns in Western blot, 
suggestive of repetitive sequences, and is therefore known as a ladder 
forming protein (similar to Alp proteins). The R3 protein do not cross-
reacted with any of the other GBS proteins identified until know
11
.  
In two recent studies of GBS from Zimbabwe, it was expressed by more than 
20% of the strains, of which 75% belonged to serotype V
10
. There was a 
higher prevalence in GBS strains from Zimbabwe than in strains from 
Norway. The studies from Zimbabwe suggest that R3 may be more 
important in certain geographic areas
5; 10
.  
Z1 and Z2 Surface proteins: Currently there are two Z proteins, which has 
been identified and described recently
5; 11
. Initially, an unrecognized protein 
antigen called Z was detected because a supposedly R3 specific polyclonal 
antibody contained Z antibodies in contrast to the R3 monoclonal 
antibodies
5
.  
Z1 was found to be expressed by:  i) a R3 reference strain (Praga 10/84, 
ATCC 49447) and ii) in 27.2% of GBS strains from Zimbabwe (usually in 
combination with R3 protein expression) and iii) in a lower number in GBS 
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strains from Norway, usually in combination with R3 protein expression. 
The new protein was shown to be similar physicochemically to R3, but 
immunologically distinct
5
.  In a subsequent study, antiserum considered to be 
Z specific contained antibodies against two different antigens as well. They 
were identified from the pattern generated by immunoblotting with the strain 
08-17 which resulted from its expression of the two proteins, later called Z1 
and Z2. The original anti-R3 polyclonal antybody contained anti-Z2 
antibodies due to the fact that for its preparation the antiserum had been 
cross-absorbed by a Z1-expressing strain but not by a Z2-expressing strain.  
The genes encoding the two Z proteins have not been identified until now. 
However, immunologic methods such: ELISA, FAT, and Western blotting 
using the polyclonal antibodies to Z1, Z2, and R3 have been used to 
characterize and find associations between these proteins.   
From the experiments using the methods previously mentioned it was 
possible to estimate the molecular mass of the proteins. Z1 is a high 
molecular mass protein of >250 kDa while Z2 is a lower molecular mass 
protein of ∼135 kDa. The Z proteins generate multiple stained bands and 
have similar chromatographic features with respect to aggregate formation 
and charge; similar to the R3 protein as well.  
Twenty eight GBS isolates of human and bovine origin from Zimbabwe and 
Norway were tested for expression of Z1, Z2 and R3 using antibody based 
methods. It was found that these GBS strains expressed one, some or none of 
these proteins. The association between the proteins varied. Twenty of the 
strains express any of the three proteins, four expressed all three antigens, 
two expressed Z2 and R3, one expressed Z1 or R3 only, and none expressed 
only Z2. In general the three proteins occurred with particularly high 
frequency (80%) in the CPS type V isolates
11
.  
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The identification and characterization of the genes that encode R3 and the Z 
proteins and studies about the relationship between them and R5 will give a 
clearer and complete landscape of the genetic basis of such GBS surface 
associated proteins. This information will help to develop molecular methods 
for a more complete GBS serotyping and to study the potential of these 
proteins as vaccine candidate components.  
 
1.3. Bacterial genome evolution 
 
Bacteria retain most of their genetic information from generation to 
generation. However, they also need to develop strategies that allow them to 
acquire new genetic material in their genomes to adapt and survive in an 
environment that change continually. Genomes of more closely related 
bacteria are more conserved but the genome variability exists within 
different genera and among different isolates of a single bacterial species.  
In the bacterial pan-genome, the ‘’core genome’’ is the conserved stable 
regions with relatively low mutational capacity containing the genes present 
in all strains. The "dispensable genome" is composed by genes that are 
present in more than one but not in all the strains, while the "unique genes" 
are specific to a single strain. The variable genome represents the total 
amount of foreign DNAs available for recipient cells. Free living bacteria 
genomes often carry phages and repetitive sequences mediating genetic 
rearrangements. Their genetic stability is associated with the genomic 
content of repeated sequences, mobile genetic elements, and influenced by 
the bacterial lifestyle. All this takes part in the bacterial genome evolution. 
The mains mechanisms that contribute to the plasticity of bacterial genome 
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are: the acquisition of DNA (gene gain), and the loss of genetic information 
(gene loss)
63
. The molecular and genetic mechanisms leading to these 
changes are summarized in the table 1-4. 
 
 Table 1-4. Mechanisms contributing to bacterial genome plasticity 63. 
Genetic element or 
mechanism Consequences 
Gain of properties 
Point mutation Alteration of gene expression 
Homologous recombination 
DNA rearrangements: inversion, duplication, deletion of 
DNA. 
Integration of horizontally acquired DNA 
Transformation Gain of additional genetic information 
IS elements, composite 
transposons 
Insertion, deletion, inversion of DNA, alteration of gene 
expression. 
Integrons Transfer of genes, DNA rearrangements 
Conjugative transposons, 
plasmids 
Conjugation 
Horizontal gene transfer 
Mobilization of other plasmids 
Bacteriophages 
Generalized or specialized transduction 
Horizontal gene transfer 
*GEIs or PAIs, pathogenicity 
islets 
Horizontal gene transfer. 
Integration and deletion of large DNA regions. 
Loss of properties 
Point mutation Alteration of gene expression, loss of function 
Homologous recombination 
DNA rearrangements, deletion of DNA, integration of 
horizontally acquired DNA 
Transposition Alteration of gene expression, loss of function 
 
*GEI, genomic island; IS, insertion; PAI, pathogenicity island. 
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1.3.1. General features and genetic evolution of the GBS Genome  
Sequencing of the GBS genome has provided valuable information to the 
understanding of this pathogen and how it cause disease in humans. To date, 
eight complete sequences  and 292 draft GBS genomes have been deposited 
in the National Centre for Biotechnology Information database (NCBI), and 
a database called Strepto-DB for comparative genome analysis of group A 
(GAS) and group B (GBS) streptococci (http://oger.tu-bs.de/strepto_db) 
64
. 
Among the complete GBS genomes some strains belong to the major disease 
causing GBS serotypes in humans and some isolates are from animal sources 
(See table 1-5).  The GBS genomes are in the range of 1,800 to 2,160 Kb in 
size with approx. 1,710 to 2,055 predicted protein coding genes and a G+C 
content about 35%.  
 
Table 1-5. GBS complete genome sequences in the NCBI database. 
GBS Strain Source Genome 
Size (Mb) 
GC% Genes Proteins 
 2603V/R Human isolate 2.16 35.6 2,279 2,127 
 09mas018883 dairy cattle 2.14 35.5 2,190 2,089 
 A909 Human isolate 2.13 35.6 2,136 1,996 
 GD201008-001 Tilapia 2.06 35.6 2,088 1,964 
 ILRI005 dairy cattle 2.11 35.4 2,256 2,155 
 ILRI112 milk of camel 2.03 35.3 2,173 2,073 
 SA20-06 Tilapia 1.82 35.6 1,872 1,710 
138P - 1.84 35.5 1831 1539 
 
The forces that drive the genome evolution of GBS have been studied by 
combining experimental and in silico approaches. Further analysis of the 
complete genome sequences using comparative genomics studies from eight 
sequenced strains from human and animal sources (2603V/R, NEM 316, 
A909, CJB111, H36B, 18RS21, COH1 and 515) has defined the composite 
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organization of GBS genomes. It was estimated that approximately 80% of 
genes belong to the core genome (minimum 1,806 genes) and around 20% to 
the dispensable genome. The number of shared genes in each genome varied 
because of gene duplications and paralogs. The number of new genes was 
decaying exponentially when a new sequence was added to the analysis. The 
number of new genes when comparing two genome sequences was in 
average 161, and this number decrease to 33 new strain specific genes after 
the eight genomes were added. The number of genes found in a single strain 
were 358 genes conformed by a varied number depending of the GBS strain 
(2603V/R (47), NEM316 (137), A909 (13), CJB111 (14), H36B (61), 
18RS21 (13), COH1 (31) and 515 (20)). In other words, the number of genes 
classified as core genome, accessory genome and strain specific genes 
depended to high degree on the number of compared strains and, the more 
strains compared the lower number of core genes, higher number of 
accessory genes, and higher pan genome. All these aspects contribute to 
GBS genetic diversity
65
.  
In addition, genes classified as strain specific genes tended to cluster in 
genomic islands. These are highly variable between the different strains and 
for instance, the analysis of the NEM316 genome revealed 14 putative 
chromosomal pathogenicity islands containing surface proteins
66
. These data 
could suggest that horizontal transfer (HGT) is an important evolutionary 
force within GBS
67
.  
HGT is the processes that permits the exchange of DNA among organisms 
both within and between species
68
. The horizontal gene transfer can occur by 
one of three main mechanisms: transformation, transduction, or conjugation. 
Transformation refers to the process when a cell takes up isolated DNA 
from the environment and has the potential to transfer DNA between 
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distantly related organisms. A second mechanism is conjugation, which is 
defined as the direct transmission of DNA from one cell to another and the 
last one, transduction, which is phage mediated transfer of genetic 
materials. In the past few years, there has been growing evidence that HGT 
may play a vital role in the evolution of bacterial genomes
69
. 
The available GSB genome sequences have been reported to contain strong 
evidence of HGT events leading to virulence acquisition and genetic 
diversity. For instance, it has been suggested that the genes encoding the 
virulence factors capsular polysaccharides and surface membrane proteins 
were acquired by HGT
70; 71
. Also, it has been demonstrated that large 
conjugal exchanges have contributed significantly to the genome dynamics 
of GBS, strengthening the understanding of the role of integrative 
conjugative elements in the dynamics of bacterial chromosomes
71
. 
Repetitive sequences are often found in the genome of GBS strains, for 
instance the genes encoding the alpha-like protein group which has a region 
with a variable number of identical, tandem repeats
72
. Other data suggests 
that small repeats (SSRs) contribute to genome plasticity in GBS. 
Comparative genomic analysis of eight bacterial genomes showed evidence 
of genotypic variation in GBS caused by slipped strand mispairing in the 
SSR regions. A total of 2,233 SSRs were identified in the GBS reference 
genome 2603V/R. When these loci were examined in seven other GBS 
genomes, a total of 56 SSR loci were found to exhibit variation, where gain 
or loss of repeat units was observed in at least one other genome, resulting in 
aberrant genotypes. Changes by such a mechanism also lead to antigenic 
variation that could be used to escape selective pressure of specific 
antibodies
73
. 
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Studies on genetic diversity in streptococcal species showed that GBS 
clusters together with S. dysgalactiae subsp.  dysgalactiae and S. 
dysgalactiae subsp. equisimilis
74
. The presence of almost identical genes, 
mosaic genes and mobile genetic elements between 55 different 
streptococcal species are signals of genetic recombination events. This is 
thought to be the main cause of genetic change in several streptococcal 
species. On the other hand, genetic diversity in GBS populations has been 
studied by different methods, like multi-locus variable number of tandem 
repeats (MLVA)
75
 and multilocus sequence typing (MLST)
76; 77
. The results 
obtained allow a better knowledge of the population structure, the genetic 
lineage and/or long-term evolutionary development of the GBS species. The 
results of MLST analyses led to the classification of GBS in different clonal 
complexes.  
1.3.2. Bacterial genome sequencing and analyses 
Bacterial genome sequencing and analysis is an important field of biological 
sciences. This approach was developed by a diverse group of scientists 
interested in a variety of topics related to genetics and the evolution. The 
mains steps that cover this field are: sequencing, assembly, ordering of 
contigs, annotation, genome comparison and extraction of common typing 
information
78
. 
Genome sequencing 
DNA sequencing is the process to determine the nucleotide order of a given 
DNA sample. Genome sequence analysis allows to get information for the 
study of organisms, such as constitutive features (predicted encoding 
regions, ribosomal RNA operons, IS elements, repeat regions, G-C content, 
origins of replication, operon structure and so on, and assignment of gene 
name and functional role(s).  
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There are different sequencing techniques. The oldest and still used has been 
the Sanger DNA sequencing method. This technique uses sequence-specific 
termination of a DNA synthesis reaction using modified nucleotide 
substrates and it was used in the Human Genome Project (1990). It is 
considered as a ‘’first generation’’ technology and since its beginning in 
1977 the method has been improved. Currently, this allows sequencing of up 
to 384 DNA fragments of up to 1.000 bp in length, with an accuracy value 
higher than 99.99%
79
.  
The genome sequencing technologies has continued progressing and 
improving over time. Newer methods have been developed and are referred 
to as next generation DNA sequencing (NGS). NGS technology combined 
with advances in bioinformatics, have resulted in what is called the new era 
of genomic science
80; 81
.  
Nowadays, genomes from humans and other model organisms have been 
sequenced. At the time of writing (04/2014), there were around 18,915 
genome projects publicly available. In total, 3 041 complete genomes were 
finished while 15,874 were available as drafts. 362 belong to studies in 
archaeas, 906 in eukaryotes and 17,647 in bacteria 
(http://www.genomesonline.org). This reflects the considerable developments 
in sequenced genomes over the past decade. 
The first bacterial genome sequenced was Haemophilus influenza
82
 followed 
by Mycoplasma genitalium
83
 in the same year (1995). They have been 
considered a milestone in microbial and genome sequencing studies
84
. 
Currently, there are more than 17.000 of microbial genome sequences 
(finished and unfinished) available in the data bases and bacterial genome 
sequencing technologies have been progressing and improving over time 
with developed instruments and platforms that allow facing the DNA 
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revolution; however, the functional analysis of encoded genes is still a 
challenge
85
.  
Next Generation Sequencing (NGS) 
There are several NGS technologies commercially available today,  
including Roche/454 FLX, the Illumina/Solexa, life/APG, Helicos 
Biosciences and the most recently launched platform Pacific Bioscience
84
.  
Among the most important aspects that distinguish one technology from 
another are the combination of specific protocols, the type and quality of 
data produced, biological applications and their cost. The steps involved in 
Next Generation Sequencing includes: template preparation, sequencing and 
imaging, and genome alignment and assembly. Due to differences in 
methodology and technology between the NGS platforms each platform has 
advantages and disadvantages that should be taken into account when 
choosing the technology to use in specific sequencing projects and for 
analysing sequence data, both own and publicly available data
80
. 
Genome assembly 
Most of the NGS technologies produce many data, but short sequence 
fragments (SRSs). These SRSs have to be assembled into continuous 
sequences referred to as ‘’contigs’’, which then need to be ordered and 
oriented to get a full genome sequence
86
.  For assembly of reads into contigs, 
several annotation systems have been developed, for instance the Roche 454 
FLX Titanium platform or the Newbler assembler from Roche.  
Newbler is a software developed for de-novo genome assembly projects 
based on the Roche 454 sequencing platform
87
. This assembler was 
developed especially for working with the reads from the Roche/454 Life 
Science sequencing technology. It has been used for many large and small 
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genome assemblies (many bacteria). However, this assembler is not open 
source software which limits its uses. 
During the assembly process, the program identifies pairwise overlaps 
between reads, constructing multiple alignments of overlapping reads.  Then 
it introduces breaks into the multiple alignments in the regions where 
consistent differences are found between different sets of reads, giving as 
result a preliminary set of contigs that represent the assembled reads. Then a 
consensus base call is generated by using quality and flow signal information 
for each nucleotide. The Output consists of the contigs based on consensus 
sequences and the corresponding quality scores.  
An additional approach to ensure correct assembly and contigs order of the 
genome is the use of physical maps constructed by restriction of the genome 
with enzyme digestion. This approach helps to improve the final genome 
assembly and also to verify the finished sequence data. Optical mapping is 
an approach to create ordered restriction maps from assemblies of single 
molecules
88
. 
After the sequencing process and the genome assembly, describing the status 
of such genome projects is important. The picture is further complicated by 
the lack of a community-accepted nomenclature that clearly defines levels of 
sequence completeness.  Two, are the most common standards for purposes 
of sequence analysis:  finished genome sequence, which represents a 
complete genome sequence, where the order and accuracy of every base pair 
have been verified. In contrast, a draft genome sequence represents a 
collection of contigs of various sizes with unknown order and orientation, 
that contains sequencing errors and possible misassembles. Finished data of 
the highest quality is the most desirable state for a genome sequence. 
However, this requires a relatively rigorous quality check and verification 
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with the aid of manual laboratory and computational processes
89
. Then, with 
the advent of the latest sequencing technologies, the terms “draft” and 
“finished” are no longer sufficient to describe the varying levels of genome 
sequence quality being produced, and  terms such as “complete draft” or 
“essentially complete”, “standard draft”, “high quality draft”, “improved 
high quality draft” and  “Noncontiguous finished” have appeared to describe 
different standards 
90
. 
Bacterial optical mapping 
Optical mapping is a method for whole genome analysis that was introduced 
in 1995
91
. It may be used for genome assembly after sequencing
92
.  The 
process comprises the creation of a genome restriction enzyme map of an 
organism, from very small quantities of high molecular weight DNA.  
The technique includes running the DNA sample through nanochannels, 
which later are fixed in place, stained, digested and visualised using an 
optical microscope
88
. The individual fragments within the molecules of DNA 
are then measured and the molecules are assembled together according to 
matching patterns of cleavage, thus creating a de-novo restriction enzyme 
map
93
. Optical mapping provides a graphical representation of the location of 
restriction sites in the whole genome of the organisms under study. The maps 
are then analysed by computer-assisted interpretation software such as 
MapSolver™ developed by the company OpGen (http://www.opgen.com/). 
This tool allows the alignment and comparison of the contiguous optical map 
with the in silico restriction map, determined for the partially complete 
whole‐genome assembly.  
In microbiology, several studies have been done using the applications of the 
optical mapping approach.  Several complete bacterial genomes have been 
assembled by integrating data from Roche 454 NGS with optical mapping 
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assembly. For instance: Providencia stuartii
94
, Xenorhabdus nemathopila 
(ATCC 19061) and X. bovienii
95
 Yersinia pestis KIM
96
, E. coli and S. 
cerevisiae among others.  
1.3.3. Gene prediction and annotation 
Assembly is followed by gene prediction and annotation.  The gene 
prediction process is the first step in genome analysis. This is a 
computational process in which regions of the DNA containing coding genes 
are identified. Annotation of a genome involves prediction of the limits of 
the genes (start codons and stop codons in all the open reading frames 
(ORFs)) and other genomic elements as well as the prediction of the function 
of the gene products. Today, the annotation of a gene involves integration of 
information from genome sequencing, bioinformatics analyses and 
experimental validation. 
Rapid Annotation using Subsystems Technology (RAST) is an automatic 
database for rapid and accurate annotation of bacteria and archea genomes, 
which has been used by many researchers for prediction of gene function and 
discovery of new pathways. It was introduced in 1997 and so far, over 
12,000 users worldwide have annotated more than 60 000 genomes using 
RAST
93
.  
The program identifies protein encoding genes, assigns gene function, 
predicts which subsystems are represented in the genome and use them to 
construct the metabolic network. In addition, RAST supports detailed 
comparison against existing genomes, determination of genes that the 
genome has in common with specific sets of genomes (or, genes that 
distinguish the genome from those in a set of existing genomes).  
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The RAST server implements two classes of asserted genes: (1) subsystem 
based assertions which are based on recognition of functional variants of 
subsystems (abstract functional roles), and (2) non-subsystem based 
assertions using integrated common approaches from a number of tools.  
RAST is composed by a set of proteins (a protein families collection called 
‘’FIGfams’’), a family function and a decision procedure.  When a new 
genome is submitted to RAST, genes are called and their annotations are 
made by comparison to the FIGfam collection. The program takes a protein 
sequence as input and decides if a protein could be added to the family by 
looking if it is globally similar to the members and shares a common 
function. They can be placed in the same family if they were located in the 
same subsystem (same functional role), the similarity region shared by the 
two sequences are above 70%, and if they come from closely related 
genomes. With these parameters, the program is able to recognize well over 
90% of the genes in a newly sequenced strain
97
.   
Basically, the steps used by RAST to get the genome annotations are: (1) call 
the tRNA and rRNA genes, (2) make initial protein-encoding genes calling 
using GLIMMER3 to get putative genes, (3) establish a phylogenetic context 
by using a small set of representative protein sequences (universal in 
prokaryotes) to find the closest phylogenetic neighbours. For each detected 
gene the starting position is adjusted and moved from putative to determined 
genes, (4) a targeted search based on FIGfams that occurs in closely related 
genomes because they are likely to be found in the new genome, (5) recall 
protein-encoding genes using the previous training set, (6) processing the 
remaining putative genes against the entire FIGfam collection, (7) clean up 
remaining gene calls to remove overlaps and adjust starting positions using 
blast to determine similarity based evidence, (8) process the remaining, 
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unannotated protein encoding genes, and finally (9) construct a metabolic 
reconstruction (a collection of the active variants of subsystems that have 
been identified) connecting genes in the new genome. The metabolic 
network is assembled using biochemical reaction information associated with 
functional roles in the subsystems
93
 . 
1.3.4. GBS   genome comparisons 
Comparative genomics is the analyses between multiple genomes of closely 
related bacteria. It has allowed a better comprehension on many genomic 
variations, answering biological questions related to bacterial evolution, 
physiology and pathogenicity. In addition, comparative genomics analyses 
have led to an improvement of the process of genome annotations
98
.  
In the special case of GBS, the availability of genome sequences has allowed 
a better understanding of the evolutionary path followed by this species that 
belongs to a genus that encompasses many harmful pathogenic species. 
Comparative genomic studies in GBS have been done by Tettelin et al.
99
 
using multiple genomes of Streptococcus agalactiae strains and other species 
of pathogenic Streptococci (S. pneumoniae and S. pyogenes) to elucidate the 
molecular basis for GBS virulence. These studies revealed that the GBS 
genome has a substantial similarity with those of the related human 
pathogens S. pyogenes and S. pneumoniae. However, GBS was shown to be 
different from the other streptococci in several metabolic pathways and 
related membrane transport systems that probably relate to adaptation to 
distinct niches in its human and animal hosts
99
. On the other hand, the study 
also revealed that there was extensive genomic intra-species diversity.  
Tettelin et al.
65
 in a later study explored gene variability within the GBS 
species using the complete genome sequence of eight GBS representing the 
five major serotypes (human isolates and one of bovine origin). The results 
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suggested the composition of the GBS genome which can be described by its 
“pan-genome” formed by a core genome and a dispensable genome that 
consists of genes shared by all the strains studied and probably encodes 
functions related to the basic biology and phenotypes of the species.   
1.3.5. Candidate gene prioritization 
The candidate gene approach has been a pioneer in many fields of genetic, 
studies including epidemiology to find casual gene variants for candidate or 
genome wide association studies. in silico tools gives fast, efficient and 
reliable results, in addition to be an alternative to costly collections of 
experimental data
100
. Accurate prioritisation of candidate genes, constitutes a 
key step in accelerating the discovery of gene functions
101
.  
In silico candidate gene prioritisation ranks genes based on the features 
associated with the genes and the function of interest. Studies suggest that 
phylogenetic profiles provide a valuable tool for predicting gene-function 
linkage.  It is because the phylogenetic profile of a gene is a reflection of its 
evolutionary history and can be defined as the differential presence or 
absence of a gene in a set of reference genomes
101
. For example, in GBS 
phylogenetic profiles of all GBS genes across 467 bacterial reference 
genomes were determined by candidate against all BLAST searches, which 
were then used to identify candidate virulence genes
101
.  
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2 AIMS OF THE STUDY 
 
2.1. Main objective  
 
The main aim of this study was to identify candidate genes for the R3 and Z 
surface-exposed proteins in two GBS strain isolated from pregnant women in 
Zimbabwe. 
 
2.2. Specific objectives 
 
 First, to get as complete as possible genome sequences from two 
Zimbabwean GBS strains GMFR293, known to express the R3, Z1 
and Z2 surface exposed proteins and CMFR30 that expresses only 
Z1. 
 To use in silico methods to identify candidate genes for the R3, Z1 
and Z2 proteins based on analysis of the sequence functional features, 
assisted by genome comparison approaches.  
 To clarify if the R5 and R3 surface proteins are identical trough 
cloning experiments. 
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3 MATERIAL AND METHODS 
 
3.1. GBS strains 
 
The reference and prototype GBS strains used in this study are listed in table 
3-1, including their capsular polysaccharide type and their serosubtype 
proteins markers.  
Table 3-1 GBS strains used in this project. 
GBS strain CPS GBS surface proteins Procedure 
GMFR293 V R3, R4, Z1, Z2 
 
Genome sequencing. 
Genome comparison. 
R5 PCR CMFR30 Ib Cβ, Z1 
2603 V/R V R4  
NEM316 (ATCC12403) III Alp2  
A909 (NCTC 11078) Ia α, β Genome comparison 
515 Ia Alp1, Z1  
04-534 IX Cα, Cβ, R3, Z1, Z2  
2603V/R V R4/ Rib  
R5 PCR 08-17 V R3, Z1, Z2 
161757 V alp3 
ComptonR 
(NCTC9828/Prage2560) 
NT R3, R4, R5a 
a R5 was tested by PCR for the gene encoding sar5, not by antibody based 
methods. 
The isolates were two strains from Zimbabwe which were chosen for 
sequencing, based on the presence of proteins markers reported in previous 
studies
11; 24
.  The GMFR293 and CMFR30 strains were found to express the 
surface proteins of interest; R3, Z1 and Z2, and Z1, respectively. The rest of 
the strains listed were GBS reference strains of different serotypes used in 
different steps through this project. Most of them have been previously 
sequenced and are published as complete or draft genomes in the NCBI 
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database.  All the strains were available at the GBS strain collection of the 
Department of Medical Microbiology, St. Olavs Hospital, Trondheim, 
Norway. 
 
3.2. Genome sequence, assembly, annotation and 
Candidate genes prioritization 
 
The procedure made to select the candidate genes coding for the R3 and Z 
surface proteins is summarized in the following flow chart, and described in 
detail in the next sections.  
 
Figure 3-1. Flow chart explaining the methodology used to obtain 
candidate genes for R3, Z1 and Z2. 
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3.2.1. Genome sequencing and assembly 
GMFR293 genome sequencing and assembly 
The procedure to get the complete genome sequence of the GBS strain 
GMFR293 considers data produced through 454 Roche pyrosequencing and 
optical mapping. 
Genome sequencing of strain GBS GMFR293 by the 454 GS-FLX sequencer 
resulted in a total of 159,529 reads of 59,021,738 bp in size. The reads were 
assembled using the Newbler GS de novo assembler software 
(www.454.com) using default assembly parameters.  
GMFR293 optical map 
In parallel to the 454 sequencing process, the same strain was sent to the 
OpGen Company (www.opgen.com) for optical restriction mapping of the 
bacterial genome. An optical map is an assembly of a number of partial 
restriction fragment maps into a single complete genome restriction map. In 
brief, the method consists of running the DNA through nanochannels (Figure 
a), fixing in place, staining, digestion with the restriction enzyme (Figure b), 
and visualization of fragments using an optical microscope interfaced with a 
digital camera. The individual fragments within the molecules of DNA are 
then stained, measured (Figure c) and assembled together according to 
matching patterns of cleavage (Figure d), thus creating a de novo restriction 
enzyme map (Figure e). 
The optical map was based on the restriction of the GBS strain GMFR293 
genome with the enzyme Ncol.  
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Figure 3-2. Steps in the creation of an optical map 
(http://www.opgen.com/) 
Genome assembly  
Using the MapSolver™ software from OpGen, the contigs from the 
assembly of reads from the 454 sequencing process were digested in silico 
with the same enzyme (Ncol) to create another optical map of the GMFR293 
contigs.  
Contigs restriction maps were aligned to the optical map of the GMFR293 
genome. Thereby, many of the contigs could be ordered and oriented. In 
cases where misassembled contigs were identified, they were broken/joined 
and realigned. Thereby some of the gaps between contigs were closed. The 
remaining gaps were identified and their sequences were found by using 
Blast alignment of all contigs on the closest reference genome to find their 
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sequences. The closest reference genome was GBS 2603V/R. It was chosen 
by creating similarity clusters between GMFR293 and several GBS genomes 
with the tool clustering of the MapSolver™ software.  
Assessment of the alignment of the in silico map of contigs and the 
optical map of the GMFR293 genome  
The assembled genome produced an in silico map. This was subjected to 
verification through identification of uncertain regions, which were 
identified searching for differences in the restriction patterns between the 
optical and the in silico maps (DRP1). The parameters evaluated to identify 
them were: missing fragments and false/missing cuts between the optical 
map and the assembled (in silico) genome. After that, the relationship 
between fragment size and relative error (RE) was calculated (see Equation 
1) in the optical map fragments, and plotted against the in silico map 
fragments.  
 
   
(                          ) (                        )
(                          )
                (1) 
 
In parallel, FASTA sequences from the GBS reference genomes A909, 
2603V/R and NEM316 (available in NCBI) were converted to in silico 
restriction maps using the MapViewer software (OpGen technologies, Inc), 
for direct comparison between the three GBS reference genomes and the 
GMFR293 optical maps. This comparison was performed to calculate 
fragments size variation, to identify restriction pattern differences (DRP2) 
and to use these data to identify which locations in the assembled genome 
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that would need to be verified through experimental work to validate the 
finished sequence. 
GBS CMFR30 genome sequencing and assembly  
The CMFR30 genome was sequenced using the PacBio RS II DNA 
Sequencing System. The sequencing process resulted in 98,249 reads with an 
average read length of 3,407 bp, and a total number of bases of 399.9 Mb. 
The obtained genome sequence was used for the comparative genomic 
analysis. 
Reads obtained from the PacBio sequencing process were assembled using 
HGAP v2 (Pacific Biosciences). The process resulted in one single contig of 
2,062,772 bp with 146,86 times average coverage. Further local assembly 
efforts were therefore not needed.  
3.2.2. Genome annotation 
The assembly of the GMFR293 genome and the sequencing of GBS 
CMFR30 was followed by gene prediction/annotation in which DNA regions 
containing coding sequences (CDSs) were identified. Annotation and 
analysis were performed using RAST
93
 (Rapid annotation using subsystem 
Technology, http://rast.nmpdr.org) which uses by default the software 
GLIMMER3 to perform gene prediction. In order to enrich the annotation 
process, functional annotations were done in addition by using the web 
server webMGA
102
  (http://weizhong-lab.ucsd.edu/metagenomic-
analysis/server/cog/), which performs function annotation by using the RPS-
Blast program at the Cluster Orthologous Groups (COG) database 
(prokaryotic proteins).  
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Physicochemical parameters of proteins  
The software ProPAS (Protein Properties Analyses Software)
103
 was used to 
calculate several physicochemical parameters of the proteins, including the 
isoelectric point (pI), hydrophobicity (Hy) and molecular weight (MW). 
CDSs coding for high MW proteins of more than 50 kDa was one of the 
parameters used to prioritize possible CGs for the R3, Z1 and Z2 proteins. 
Prediction of Genomic Islands (GEIs) 
GEIs are discrete DNA segments, which may be mobile or not, or no longer 
mobile, which differ among closely related strains
104
. In GMFR293 and 
CMFR30 genomics islands were predicted by using the IslandViewer 
software tool (http://www.pathogenomics.sfu.ca/islandviewer) 
which integrates the two sequence composition GI prediction methods SIGI-
HMM and IslandPath-DIMOB, and a single comparative GI prediction 
method IslandPick
105
. In this process, default parameters were used.  
Proteins topology 
The methodology used to predict the potential location of the encoded 
proteins in the GMFR293 and CMFR30 genomes was based on prediction of 
transmembrane helix (TMH) and of retention of signal sequences that govern 
the transport and localisation of a protein in a cell. This was done to identify 
CDSs encoding potential surface exposed proteins, which could be 
membrane or secreted protein. 
Transmembrane helix prediction (TMH) 
Transmembrane helices are characteristic for membrane proteins.  In this 
study we used TMHMM (a hidden Markov model (HMM)) for predicting 
the number of transmembrane helices, their location, and in/out orientation to 
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all the CDSs in the GMFR293 and CMFR30 genomes.  Proteins predicted as 
transmembrane were considered potential candidate genes for the R3, Z1 and 
Z2 proteins.   
Identification of motifs or domains   
Pfam (http://pfam.sanger.ac.uk/) and HMMER 
(http://www.cbs.dtu.dk/services/TMHMM/) were used to search motifs 
described as cell wall anchoring or binding domains in Gram positive 
bacteria included Streptococci. Motifs or domains detected were considered 
significant if they obtained a score higher than 10 and the per-domain E-
value was lower than 0.1
106
. These were used as query profiles in the 
analysis of the CDSs from the GMFR293 and CMFR30 genomes.  
ScanProsite (http://prosite.expasy.org/) was used for pattern recognition of 
lipoprotein, LPxTG and YSIRK signals, and SIGNALP 
(http://www.cbs.dtu.dk/services/SignalP/)
107
 was used to identify signal 
peptides. Candidate lipoprotein signal peptides were flagged by matches with 
the pattern {DERK}(6)-[LIVMFWSTAG](2)-[LIVMFYSTAGCQ]-[AGS]-
C 
99
.YSIRK signal through the pattern [WYF][ST][IL][RK][KR]xxxGxxSV 
and LPxTG signal by matches with the pattern [LIF]PXT[GSN]. 
3.2.3. In silico genome comparison 
Protein coding genes of GMFR293 and CMFR30 were compared against 
each other and also against genomes of four reference strains: A909, 
NEM316, 515 and 2603 V/R. The comparison was done by RAST 
comparison tool at the protein sequence level using BLASTP. Genome 
comparison was used to assist the selection of the CGs and to identify novel 
surface proteins.  
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3.2.4. In silico prioritization of candidate genes  
The strategy followed for finding candidate genes was based on two 
complementary approaches. One was to compare the GMFR293 and 
CMFR30 genomes to related reference genomes published in the NCBI 
database, while the other approach was to test protein-encoding regions in 
the genome for properties associated with the proteins of interest, as MW 
and potential for being surface exposed proteins. The potential candidate 
genes presented the following attributes:  
 CDSs encoding proteins with a MW higher than 50 kDa. This 
criterion was based on the assumption that R3, Z1 and Z2 are high 
molecular weight proteins. 
 CDSs with predicted functional annotations as membrane 
associated, surface associated or hypothetical proteins. 
 CDSs encoding proteins predicted as potential surface located or 
secreted. This criterion was based on the knowledge of surface 
exposition of  R3, Z1 and Z2 proteins. Proteins predicted to have 
TMH are potential TM, proteins retaining LPxTG or YSIRK signals 
are predicted to be covalently or transiently linked to the cell wall and 
proteins carrying signal peptides are features of secreted proteins or 
lipoproteins.  
 
3.3. Analysis of the sar5 gene in relation to the 
expression of the R3 surface protein 
 
In order to clarify if R3 and R5 are identical proteins, two procedures were 
used. First, a variety of R3 positive reference and prototype GBS strains 
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were tested using the sar5 PCR and secondly, we cloned the gene encoding 
the R5 surface protein (sar5) behind an inducible promotor on plasmid 
pET15. The resulting plasmid (pET15sar5) were introduced into E.coli 
BL21cell and the strains containing the plasmids were then tested for R3 
expression by immunofluorescence.   
3.3.1. Bacterial strains, growth and media  
GBS strains used for the experiments are listed in table 3-1. Additionally to 
the GBS strains, E. coli DH5α cells (plasmidic DNA production cells 
(pDNA)) and E.coli BL21 cells (recombinant protein production cells) from 
Life technologies were used for cloning experiments. 
GBS strains stored at -80°C were grown over night (ON) on blood agar 
plates. E.coli cells stored at -80°C were grown ON in Luria-Bertani (LB) 
broth, unless otherwise specified. E. coli bacteria were grown onto LB agar 
with the presence of 100 µg of ampicillin/ml or on LB agar plates containing 
IPTG (inducer) when this was needed. Incubations were performed at 37°C, 
ON. 
3.3.2. Chromosomal DNA extraction from GBS strains 
For nucleic acid extraction, one colony was picked from subculture on a 
blood agar plates and added to 300 µl of a lysis solution containing 273 µl of 
Tris-EDTA (TE) buffer, 15 µl of lysozyme (20 mg/ml), 6 µl of proteinase K 
(20mg/ml) and mutanolysin (10.000 U/ml). The mixture was incubated at 
37°C and 65°C for 15 minutes each.  DNA was purified using the Qiagen 
column from the DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany) 
and eluted in a volume of 50 µl.  
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3.3.3. Oligonucleotide primers and PCR amplifications 
The primers set used in this work and their sequences are listed in Table 3-2. 
The primers were designed based on the published sequence of the sar5 gene 
of GBS Compton R (EMBL accession number AJ133114.1).  The first 
primer set (reported previously
24
 ) was used to detect the sar5 gene in the 
prototype and reference GBS genomes. Primer sets two and three were 
designed using the program Clone Manager 9 (Sci-Ed Software, 
http://www.scied.com/pr_cmbas.htm ), to amplify the full-length sar5 gene 
by PCR. These primers included restriction endonuclease recognition sites to 
enable subsequent cloning into a modified expression vector. 
Table 3-2. Primers sets used through the experiments 
Primer 
set 
Primer 
name 
Primer sequence 5’-3’ 
1 Sar5 Forward  CGTAAATTTTCGGTTGGAATAGC 
Sar5 Reverse GACGAACCACCGTTGTTTCAG 
2 R5 F Xhol GTCAACTCGAGATGTTTCGTAAATATAATTTTG 
R5 R BamHI GAGCTGGATCCATCTATGATGTGATTATTAAC 
3 R5 trunc F Xhol GTCAACTCGAGACTCCAACAGGTG 
R5 R BamHI GAGCTGGATCCATCTATGATGTGATTATTAAC 
 
Amplification was carried out in a final volume of 25 µl containing the Tag 
Polymerase Promega® buffer 1X (10 mM Tris-HCl, pH 8.3; 50 mM KCl; 
0.1% Triton® X-100); 1.5 mM de MgCl2; 200 µM from each dinucleotide 
(dATP, dCTP, dGTP, and dTTP (Promega®), 0.4 µM of each primer; 1.5 
units from the Taq Polymerase Promega® enzyme, and 1 µl from the DNA 
sample. The amplification conditions used are listed in table 3-3. 
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Table 3-3.  PCR cycling conditions used through the experiments 
 
Primer 
Set 
Amplification phases No  
of  
cycles Initial 
denaturation 
Denaturation Annealing Extension 
 
Final  
extension 
1 96°C/5min 95°C/1min 58°/45sec 72°C/10min 10°C/ 36 
2 96°C/5min 65°C/1min 50°C/45sec 72°C/10min 10°C/ 36 
3 96°C/5min 65°C/1min 53°C/45sec 72°C/3min 10°C/ 36 
 
The amplification products were visualized through electrophoresis in 1.0% 
agarose gels stained with ethidium bromide. To estimate the size of the 
amplified product, two molecular weight patterns were used: 1 kb DNA 
Ladder with a reading range between 10,000 and 250 bp, and a molecular 
weight pattern 2-Log DNA Ladder with fragments ranging from 100 bp to 
10 kb, both from New England BioLabs®inc. 
3.3.4. Identification and cloning of the Sar5 gene 
Amplified fragments were cloned behind an inducible promoter on plasmid 
pET15b (Novagen (EMD Millipore)) and introduced into the pDNA 
production cells E.coli DH5α. It was done by ligating the Ncol/BamHI 
fragment of Sar5 gene into Ncol/BamHI pET-15b and transforming the 
E.coli DH5α competent cells. Then, the plasmid carrying the sar5 gene 
(pET15sar5) were introduced into E.coli BL21 cells and the strain 
containing the plasmids were streaked onto agar plated containing IPTG 
(inducer).  Description is presented as follows: 
Following PCR amplification (using primer set 2 and 3), the full-length 
products were digested with the restriction enzymes Xhol and BamHI. 
Digested products were purified using the QIAquick PCR Purification Kit of 
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QIAGEN and cloned into the vector pET15b which carries an N-terminal 
His•Tag® sequence followed by a thrombin site and multiple cloning sites. 
Plasmid DNA was prepared using the PureYield™ Miniprep System from 
Promega®. The vector was previously digested with the same restriction 
enzymes used to digest the PCR products, allowing insertion of the sar5 
gene into the vector. The resulting recombinant plasmid (pET15sar5) were 
used to transform the E. coli DH5α competent cells by the heat shock 
transformation method. Briefly, 10µl of the PCR product was mixed with 2µl 
of (10x) T4 ligase buffer, 4 µl of pET15b vector (40ng/µl), 2 µl of T4 DNA 
ligase and 3µl of deionised water. The mixtures were incubated ON to 16°C. 
Transformations of E. coli DH5α cells were made by mixing 5µl of the 
ligation reaction mixture with 50µl of competent cells on ice (20 min), heat 
shocking the cells at 42°C (30 sec) and cooling on ice (2 min). Then, LB 
medium (1ml) was added and the mixture was incubated at 37°C for two 
hours. Transformed cell cultures were plated on LB agar plates containing 
ampicillin (100µg/ml) and incubated at 37 °C ON.  
To confirm that the pDNA producers contained the sar5 gene, colony growth 
on LB agar plates containing ampicillin (100µg/ml) was grown in 2ml of LB 
ON. Plasmids were purified by the PureYield™ Miniprep System from 
Promega® and digested with the same restriction enzymes. The restrictions 
were checked to fragments of correct molecular weight through 
electrophoresis in 1.0% agarose gels stained with ethidium bromide. The 
transformation was also confirmed trough PCR using the plasmid DNA and 
the primers reverse sar5 and R5 trunc F Xhol. Untransformed E.coli DH5α-
cells were tested as control. 
Then, the resulting plasmids produced by the E.coli DH5α-cells (pET15sar5) 
were introduced into E.coli BL21 (recombinant protein production cells) and 
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the strain containing the plasmid was streaked onto agar plated containing 
IPTG (inducer).    
3.3.5. Test of sar5 transformants for R3 expression 
E. coli LB21 sar5 transformants were tested for R3 surface protein 
expression by immunofluorescence using rabbit polyclonal antibodies (PAs) 
raised against the R3 reference strain GBS Prague 25/60 (ATCC9828)  
previously shown to contain antibodies against R3. Slides for 
immunofluorescence testing were prepared from  E. coli LB21 culture on LB 
medium and the testing was performed essentially as described in 
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. The 
antiserum was used diluted 1:50 and 1:200, respectively, and R3 expression 
was tested by using fluorescent anti-rabbit IgG antibodies.  
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4 RESULTS 
 
4.1. GBS strain GMFR293 genome sequencing and 
assembly 
 
The data obtained from 454 pyrosequencing and optical mapping allowed 
assembly of GMFR293 into a complete genome. First, sequencing of 
GMFR293 by 454 pyrosequencing resulted in a total of 159,529 reads of 
59,021,738 Kb in size, with about 28 fold coverage of the genome.  In total, 
48 contigs with an average size of 55,582 bp and a median contig size (N50 
value) of 133,175 were produced when the reads were assembled, using the 
assembly software Newbler.  
By optical mapping of genomic DNA of strain GMFR293 restriction cut by 
Ncol, 196 fragments and 195 restriction cuts were identified. By this method 
the total size of the genome was estimated to 2,029,591 bp, with fragments in 
the range from 1,723 bp to 79,393 bp.  
By aligning an in silico restriction map of the contigs from the assembly of 
sequencing reads using restriction cut sites similar to that of Ncol to the 
optical map, 78 % of the genome sequence assembly (11 contigs) was 
covered while 37 of the contigs did not align with the optical map. All 
contigs were then aligned with the most similar reference genome of strain 
GBS2603 V/R (Figure 4.1). This allowed closure of the gaps and completion 
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of the genome. The final GMFR293 in silico map composed of 235 
restriction fragments had a size of 2,033,090 bp. 
 
Figure 4-1. Phylogenetic tree showing similarity at genome level between GBS 
strain GMFR293 and other complete GBS genomes, including the most similar 
genome of reference strain 2603 V/R. 
 
4.1.1. Assessment of GMFR293 genome assembly 
To assess accuracy of the GMFR293 genome assembly, the optical 
restriction map and the generated in silico restriction map of assembled 
contigs were compared. A total of 67 fragments were classified as uncertain 
regions due to differences between the optical restriction map and the in 
silico restriction pattern (Appendix A contains the full list of these 67 
uncertain regions). Among these were 27 fragments which were present in 
the in silico map but not in the optical map, and 40 fragments which were 
shared between the maps, but where there were differences in the fragment 
size. Relative sizing error was calculated (Figure 4-2), and for nine 
fragments the error was higher than 10% (Figure 4-3). 
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Figure 4-2. Plots of optical map fragment sizes versus in silico restriction map 
fragment sizes of 40 uncertain regions. 
 
Figure 4-3. Relative fragment size error rate versus in silico restriction map sizes 
of 40 fragments from identified uncertain regions. 
When the uncertain regions of the GMFR293 in silico map were compared 
with the in silico restriction maps of the three GBS references genomes of 
strain 2603V/R, A909 and NEM316, 16 fragments were found to have 
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different restriction patterns and 51 had identical restriction pattern with at 
least one of the reference genomes. Five of the 16 fragments had a different 
size, and 11 were unique for the GMFR293 in silico map. 
Finally, after analysis of all the parameters evaluated, 29 fragments in the 
assembled genome, corresponding to 8.7% of the GMFR293 total genome, 
with fragment sizes between one and 28,186 bp (Figure 4-4) were still 
considered uncertain which should therefore preferably be subjected to 
experimental verification (Appendix B contains the full list of uncertain 
regions selected to verification), in order to confirm the accuracy of the 
finished sequence.  
 
Figure 4-4 Ascending ordered fragment number versus fragment size in Kb 
of places in the genome assembly that must be verified experimentally to 
obtain a finished genome. 
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4.2. General features of the GMFR 293 and CMFR30 
genomes 
 
The complete GMFR293 genome without verification of the remaining 
uncertain regions mentioned above, consisted of a single circular 
chromosome of 2,037,090 bp, with a G+C content of 35.5%, containing 
2,023 coding sequences (CDSs) with putative predicted protein encoded 
genes. The genome contained 95 RNAs composed by 74 tRNA, 14 rRNAs, 
and 7 sRNAs (see figure 4-5).  
 
Figure 4-5 Circular representation of the genome of GBS strain GMFR293, 
analysed by Geneious version 7.1.108 Arrows: Pink, tRNAs; Red, rRNAs; Green, 
Genomic islands. Inner AT graph (in green) and GC content (in blue). 
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The complete CMFR30 genome consisted of a single circular chromosome 
of 2,062,772 bp, with a G+C content of 35.4%. There were 2,060 coding 
sequences (CDs) with putative predicted protein encoding genes. The 
genome contained 88 RNAs composed by: 70 tRNA, 12 rRNAs, and 6 
sRNAs (see figure 4-6). The general features of both the sequenced GBS 
genomes are presented in table 4-1. 
 
Figure 4-6 Circular representation of the CMFR30 genome, analysed by Geneious 
version 7.1 108. Arrows: Pink, tRNAs; Red, rRNAs; Green, Genetic islands. Inner AT 
graph (in green) and GC content (in blue).  
Table 4-1. General features of the GMFR293 and CMFR30 genomes. 
Strain Replicon Size bp GC% CDs tRNA rRNA 
GMFR293 Chrom 2.037.090 35.5 2023 74 14 
CMFR30 Chrom 2.062.772 35.4 2060 70 12 
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In order to obtain more complete information about the gene coding 
sequences in the genomes, functional annotations were grouped into COG 
functional categories and FIGfams-subsystems (RAST).  
The gene distribution of the two GBS genomes according to their COG 
functional categories is presented in table 4-2, and the statistics from the 
annotation process through COG functional categories is presented in table 
4-3. 
Table 4-2. Number of genes associated with the general COG functional 
categories in strain GMFR293 and CMFR30. 
Code Description GMFR293 CMFR30 
  Value % Value % 
C Energy production and conversion 56 2.76 55 2.71 
D 
Cell cycle control, cell division, 
chromosome partitioning 25 1.23 24 1.18 
E Amino acid transport and metabolism 152 7.51 148 7.31 
F Nucleotide transport and metabolism 83 4.10 84 4.15 
G Carbohydrate transport and metabolism 167 8.25 186 9.19 
H Coenzyme transport and metabolism 55 2.71 56 2.76 
I Lipid transport and metabolism 52 2.57 50 2.47 
J 
Translation, ribosomal structure and 
biogenesis 149 7.36 152 7.51 
K Transcription 134 6.62 137 6.77 
L Replication, recombination and repair 114 5.63 123 6.08 
M Cell wall/membrane/envelope biogenesis 106 5.23 107 5.28 
N Cell motility 9 0.44 6 0.29 
O 
Posttranslational modification, protein 
turnover, chaperones 53 2.61 59 2.91 
P Inorganic ion transport and metabolism 102 5.04 109 5.38 
Q 
Secondary metabolites biosynthesis, 
transport and catabolism 23 1.13 20 0.98 
R General function prediction only 213 10.52 215 10.62 
S Function unknown 167 8.25 172 8.50 
T Signal transduction mechanisms 76 3.75 83 4.10 
U 
Intracellular trafficking, secretion, and 
vesicular transport 26 1.28 23 1.13 
V Defence mechanisms 44 2.17 47 2.32 
- Not in COGs 217 10.72 208 10.28 
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Table 4-3. Functional genome annotations through COGs of the GBS 
strains GMFR293 and CMFR30  
Strain Total 
number 
of genes 
Genes with 
assigned 
function 
Function 
unknown 
Not in 
COGs 
Assigned 
to COGs 
GMFR293 2023 1639 
 (81%) 
167  
(8.2%) 
217  
(10.7%) 
1806 
 (89.3%) 
CMFR30 2064 1684  
(81.6%) 
172 
 (8.3%) 
208  
(10%) 
1856  
(89.9%) 
 
Almost one third of the genes in each of the two GBS genomes were 
predicted as hypothetical proteins when they were annotated by RAST. The 
statistical values of this annotation process are presented in table 4-4, 
including the description of the steps that the RAST server implemented to 
automatically produce the two classes of asserted gene functions: subsystem-
based assertions are based on recognition of functional variants of 
subsystems (Collection of functional roles jointly involved in a biological 
process) while non-subsystem based assertions are filled in using more 
common approaches based on integration of evidence from a number of 
tools. 
In the genome of GMFR293 400 CDSs were annotated as hypothetical 
proteins; 16 CDSs as surface-associated, 65 CDSs as membrane associated 
and 11 CDSs as cell wall associated by annotation with RAST,. In 
comparison, in the CMFR30 genome 390 CDSs were annotated as 
hypothetical proteins, 18 CDSs as cell surface-associated 69 CDSs as 
membrane associated and 15 CDSs as cell wall associated proteins. The 
latter were the first CDSs evaluated as potential CG for R3, Z1 and Z2 
surface exposed protein. 
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Table 4-4. Statistics of the annotation process through RAST pipeline 
annotation. 
 
In addition, molecular weights (MW) were calculated for all CDSs that were 
present in both genomes. This was done in an attempt to identify the R3, Z1, 
and Z2 by their molecular weight, which had been estimated to around 140 
kDa for R3, 250 kDa for Z1 and 135 kDa for Z2 in a previous study.  
Most predicted proteins of the GMFR293 and GBS CMFR30 genomes were 
in the range of 4.1 ±1 to 172.3 kDa. From the 2,024 CDSs that constituted 
the complete GMFR293 genome and the 2,064 CDSs that constituted the 
genome CMFR30, 29 and 30 CDSs, respectively, had molecular weight of 
more than 100 kDa.  However, there were no proteins with a molecular 
weight as high as that predicted for Z1 (250 kDa). Based on this result, the 
range of MW used as filter to target CDSs for CG was adjusted to higher 
 
 
Strain 
Total 
number 
of CDSs 
 
 
Coverage 
 
 
Annotation 
Number of 
Hypothetical 
Proteins 
Number of non-
Hypothetical 
proteins 
 
 
 
GMFR293 
 
 
 
2023 
 
In 
subsystems 
1102 (55%) 
Hypothetical 
46 (4.2%) 
 
 
 
400 
(19.8 %) 
 
 
 
1623 
(80.2%) 
Non hypothetical 
1056 (95.8%) 
 
Non-in 
subsystems 
921 (45%) 
Hypothetical 
354 (38.43%) 
Non hypothetical 
567 (61.6%) 
 
 
 
CMFR30 
 
 
 
2064 
 
In 
subsystems 
1139 (56%) 
Hypothetical 
48 (4.2%) 
 
 
 
390 
(18.9%) 
 
 
 
1674 
(81.1%) 
Non hypothetical 
1091 (95.8%) 
 
Non-in 
subsystems 
925 (44.8%) 
Hypothetical 
342 (37%) 
Non hypothetical 
583 (63%) 
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than 50 kDa. Based on this filter, 321 CDSs of GMFR293 and 242 CDSs of 
CMFR30 were selected as candidate genes for for R3, Z1 and Z2. 
4.2.1. Genomic islands (GIs) 
Strains GBS GMFR293 and CMFR30 possess several virulence factors, GIs, 
transposons and insertion sequence (IS) elements, distributed over their 
genomes. It is well known that genes contributing to pathogenesis frequently 
are located in such genomic Islands. 
Strain GMFR293 contained six putative genomic islands (see figure 4-6) 
incorporating 91 predicted genes, many of which were mobile elements. The 
genomic islands were composed of 10 to 25 genes with molecular weights 
between 4.7 kDa and 93 kDa. 43 of these genes were predicted to encode 
hypothetical proteins and 25 were predicted to be transmembrane proteins. 
Nine of the 25 genes were hypothetical proteins and predicted to be 
transmembrane proteins. We also checked if the gene sar5 encoding the R5 
surface protein was part of a genomic island, but it was not present in any of 
the predicted genomic island in GMFR293. 
Isolate CMFR30 contained seven putative genomic island (see figure 4-7) 
incorporating 79 predicted genes. The islands were composed of 6-22 genes 
with molecular weight in the range of 4.4 kDa to 128 kDa.  29 genes were 
predicted to encode hypothetical proteins and 19 were predicted to be 
transmembrane. 13 of the predicted CDSs were classified both as 
hypothetical and transmembrane proteins.  
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4.2.2. Known surface proteins in GBS GMFR293 and GBS 
CMFR30  
Surface proteins in Gram-positive bacteria are frequently implicated in 
virulence. In GBS, numerous genes have been identified as genes encoding 
surface proteins. These proteins together with secreted products are 
identified as potential virulence factors. 
After annotation of the GMFR293 and CMFR30 genomes, it was possible to 
identify previously sequenced GBS surface proteins. Some of the known 
surface proteins found in both GBS genomes were: C5a peptidase, cold 
shock protein CspA, surface protein Rib, sortase A (one in CMFR30 and 
three in GMFR293), fibronectin/fibrinogen-binding protein, hyaluronate 
lyase precursor, laminin-binding surface protein, group B streptococcal 
surface immunogenic protein and the CAMP factor.  
4.2.3. Prediction of surface exposed proteins 
The prediction of proteins carrying signature motifs to Gram positive surface 
proteins is important because the carriage of signal peptides is involved in 
the protein secretion and surface display in such bacteria. Therefore an 
attempt was done to predict potential subcellular locations of the proteins 
encoded by the GMFR293 and CMFR30 genomes. The aim was to identify 
CDSs encoding potential surface exposed and secreted proteins. The results 
for both GBS strains are presented in the table 4-5. 
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Table 4-5 Results of the prediction of transmembrane helix (TMH) and 
signature motifs in the GMFR293 and CMFR30 genomes. 
Parameter 
Predicted 
GMFR293 CMFR30  
Meaning Total 
CDSs 
CDSs 
>50kDa 
Total 
CDSs 
CDSs 
>50 kDa 
 
TMH 
536 
(26.5%) 
113 
(5.58%) 
545 
(26.40%) 
70 
(3.39%) 
Characteristic of 
membrane proteins 
 
 
Signal 
Peptides 
 
114 
(5.36%) 
 
31 
(1.53%) 
 
114 
(5.52%) 
 
27 
(1.30%) 
Found in proteins that 
are secreted, retained 
or proteins that cross 
the membrane only 
once (single pass).  
YSIRK 
Signal 
7 
(0.34%) 
4 
(0.19%) 
7 
(0.33%) 
6 
(0.29%) 
 
Found in protein with 
potential to be 
secreted into the cell 
wall. 
LPxTG 
Signal 
58 
(2.86%) 
13 
(0.64%) 
64 
(3.10%) 
26 
(1.26%) 
Lipoproteins 111 
(5.48 %) 
14 
(0.69%) 
108 
(5.23%) 
16 
(0.77%) 
Lipoproteins 
 
CDs predicted to encode TM, and/or proteins carrying signals peptides were 
selected, and included in the final list of CG for R3, Z1 and Z2 proteins 
(Appendix D contains the full list of CDSs) as well as for the Z1 protein 
(Appendix E contains the full list of CDSs). 
 
4.3. Comparison of the GMFR293 and CMFR30 
genomes against reference GBS genomes 
 
The pan-genome is the entire gene repertoire in a selection of a strain or a 
species, representing the sum of the above mentioned core genome and the 
dispensable genome. In previous studies it was found that strain GMFR293 
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expressed the proteins R3, Z1 and Z2 and contained the sar5 gene; strain 
CMFR30 expressed Z1 but was sar5 negative by PCR analysis, and the GBS 
reference strains A909, NEM316, 2603 V/R and 515 were negative for the 
expression of all the three proteins and were sar5 negative by PCR analysis. 
In this study we did a comparative analysis based on protein sequence 
homology.  CDSs of the GMFR293 and CMFR30 genomes were compared 
against the five complete GBS genomes A909, NEM316, 2603 V/R, 515 and 
CMFR30 and/or GMFR293. The aim of the comparison was to identify 
candidate genes for the R3, Z1 and Z2 proteins by analysis of the occurrence 
pattern (absence/presence) and the grade of similarity between the genes.   
In general, the number of genomes that are included in a comparison 
influences on the distribution of CDSs between the core and dispensable 
genome of each strain, and the number of genes which are unique to each 
genome.  (See figure 4-7).  
 
 
Figure 4-7 Comparative analysis of CDSs of the GMR293 genome with five GBS 
reference genomes. Colours indicate the number of genes that were present in 
all or just a subset of the genes, depending on how many genomes that were 
compared 
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CDSs highly conserved in the GBS  genomes which were compared, CDSs 
shared between the genomes and strain specific genes in GBS GMFR293, 
and CMFR30 could be identified after the  sequence-based comparison (see 
figure 4-8 for an illustration of  the comparison of GMFR293). 
 
Figure 4-8  Circular map with color-coded table showing sequence identity of four 
reference GBS genomes compared to GMFR293, using the RAST sequence based 
comparison tool. The colours represent changes in conservation relative to the 
reference genome GMFR293. Colours going from blue representing highest 
protein sequence similarity to red representing the lowest. Each gene is marked 
as being unique, a unidirectional best hit or a bidirectional best hit in comparison 
to the reference genome.  The order of the circles from the inner to the outer is 
as follow: A909, 2603V/R, CMFR30 and 515.  
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4.3.1. GBS GMFR293 genome comparison 
Compared to the CMFR30, 515, A909, 2603 V/R and NEM316 GBS 
genomes, 14 genes were identified as strain specific genes for GMFR293 
(see table 4-6), and the proteins encoded by these genes were estimated to be 
in the range of 4.25 kDa to 35.09 kDa. Most of the CDSs were annotated as 
hypothetical protein encoding genes, four were predicted to be part of the 
genomic island III, and none of the CDs in this group of strain specific genes 
were classified as transmembrane or carrier of signal peptides.   
Table 4-6 GMFR293 strain specific genes. 
CDS Start End Annotation 
MW 
(kDa) Topology 
Genomic 
Island 
(GI) 
303 320618 320505 hypothetical protein 4.25 outside 
 559 569880 570050 hypothetical protein 6.33 inside 
 560 570227 570667 Phage protein 17.24 outside 
 562 571695 572537 DNA replication protein  31.89 outside III 
563 572537 572683 hypothetical protein 5.75 outside III 
564 572673 572948 hypothetical protein 10.86 outside III 
581 580027 580935 Phage protein 35.09 outside III 
892 906624 906755 hypothetical protein 5.25 outside 
 1189 1206597 1206220 hypothetical protein 14.82 outside 
 1384 1411217 1411354 hypothetical protein 5.32 outside 
 1671 1680553 1680675 hypothetical protein 4.75 outside 
 1744 1761221 1761352 hypothetical protein 4.98 outside 
 1874 1882814 1882647 hypothetical protein 6.59 outside 
 1891 1894488 1894631 hypothetical protein 5.59 outside 
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A total of 180 CDSs from GMFR293 had a similarity percentage less than 
100% when compared with CDSs in the other five GBS genomes. There 
were 57 CDSs which were predicted as transmembrane and annotated as 
hypothetical proteins, 43 CDSs had a molecular weight higher than 50 kDa, 
and these were therefore selected as candidate CDSs for R3 and Z2, 
especially those predicted to be potential surface exposed from the previous 
analyses. The features presented by the members of this group are 
represented in the table 4-7. 
Table 4-7 Features of the target CDs for R3 and Z2 CGs obtained through 
the GMFR293 CDs comparative analysis. 
CDSs Features No of 
CDSs 
Signal 
peptide 
Lipo- 
proteins 
YSIRK 
signal 
LPxTG 
signal 
CDSs with molecular weight 
higher than 50 kDa 
43 5 2 3 2 
CDSs with molecular weight 
lower than 50 kDa 
137 7 6 4 1 
TOTAL of CDSs with similarity 
less than 100% 
180 12 8 7 3 
 
4.3.2. CMFR30 genome comparison  
The comparative analysis of the CMFR30 CDSs against the GMFR293, 515, 
A909, 2603 V/R and NEM316 GBS genomes was done in order to identify 
candidate CGs for the Z1 protein, especially searching for CDSs more 
similar with CDSs in GMFR293, and absent or less similar with CDSs in the 
other genomes.   
After the comparison with the other GBS genomes, 48 CDSs were identified 
as CMFR30 strain specific based on absence or similarity to other genomes 
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of less than 50%. The molecular weight of the encoded proteins in this group 
was in the range of 3.8 kDa to 63.2 kDa.  25 CDs were annotated as 
hypothetical proteins and six were predicted to belong to a genomic island 
(GI) (Appendix C contains the full list of the CMFR30 strain specific CDSs).  
All the CDSs that were 100% identical between the CMFR30 and GMFR293 
genomes and a similarity less than 100% with the reference genomes were 
selected for further analyses. Using that criterion, eight genes were identified 
with MWs in the range of 4.1 kDa to 80.01 kDa. However, only one of the 
CDSs had a molecular weight higher than 50 kDa.  
 
4.4. R3, Z1 and Z2 candidate genes  
 
The in silico approach allowed the identification of 32 CDSs in the CMFR30 
genome with potential to be CGs for the Z1 protein. 26 of these were 
annotated to have a putative function and six as hypothetical proteins or 
proteins of unknown function. Many of them exhibited features similar to 
GBS surface proteins previously identified (see figures 4-9 and 4-10 for 
some examples). 14 CDSs were found sharing a similar organizational 
pattern:  a N-terminal signal peptide and a C-terminal LPxTG motif. Five of 
them carried an YSIRK motif which is positioned within the signal peptide at 
the start of the transmembrane domain and six CDSs were predicted as 
carriers of the consensus sequence of lipoprotein precursors.  
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Figure 4-9  Graphs showing the prediction of transmembrane regions (TMHMM) and 
prediction of the domain architecture (Pfam) of the GBS proteins Cα (GenBank: 
M97256.1) and R5 (BPS) (GenBank: CAB46338.1).  
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                      CDS_1305_GMFR293 
 
 
Figure 4-10 Graphs showing the prediction of TM regions (TMHMM) and the domain 
architecture (Pfam) from two CGs (CDS-1242 and CDS-1305) obtained from the GMFR293 
sequence analysis and one of the selected CGs for the Z1 surface protein (CDS-159) 
obtained from the CMFR30 sequence analysis.  
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51 CDSs were identified with potential to be CGs for the R3 and Z1 and Z2 
proteins in the GMFR293 genome. 36 of these were annotated to have a 
putative function and 15 as hypothetical proteins or proteins of unknown 
function. Similar to the CGs in the CMFR30 genome, many of them 
exhibited features similar to GBS surface proteins previously identified (see 
figures 4-9 and 4-10 for some examples). Four CDSs had a N-terminal signal 
peptide and a C-terminal LPxTG motif and one of them was predicted to 
carry additionally an YSIRK signal. Five CGs had an YSIRK signal motif 
and were predicted to carry a signal peptide. Fourteen CDSs were predicted 
as carriers of the consensus sequence of lipoprotein precursors. N-terminal 
signal peptides and a C-terminal LPxTGs are characteristic of cell wall 
associated proteins. Some proteins have in addition, an YSIRK signal 
positioned within the signal peptide at the start of the transmembrane 
domain.  Lipoproteins are considered to be directly anchored to the 
cytoplasmic membrane. 
 
4.5. Sar5 as candidate gene for the R3 surface 
display protein 
 
Reference and prototype GBS strains that in a previous study expressed one 
or more of the surface exposed proteins in question (R3, Z1, and Z2) by 
immunofluorescence were tested by PCR for the presence of the sar5 gene. 
In sar5 positive samples a PCR product of 417 bp, as expected for this gene 
was detected by gel electrophoresis (see figure 4-11).  All the strains 
previously serotyped as R3 positive were positive for the R5 PCR, including 
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the GBS strain 2603V/R which had been reported previously as sar5 
negative
24
 (See table 4-7). 
 
 
Figure 4-11  Electrophoresis gel obtained from sar5 PCR. Ladder 1Kb. 
 
Table 4-7. PCR results for the sar5 gene. 
GBS Strain Serotype Sar5 PCR 
GMFR293 V/R3,Rib, Z1,Z2 + 
CMFR30 Ib/Cα,Cβ,Z1 - 
04-534 XI/ Cα, Cβ, R3, Z1, Z2 + 
2603V/R V/R4/ Rib + 
08-17 V/R3, Z1, Z2 + 
161757 V/alp3 - 
*Compton R (NCTC 9828/Prage 2560) NT/R3, R4, R5 + 
*Strain used as PCR positive control. 
In addition, the sar5 appeared as one of the CG for R3 (CDS-1223) in the in 
silico analysis of the CDSs from the GMFR293 genome. This CG was 
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annotated as a hypothetical protein of 105.62 kDa, predicted as TM, and 
carrier of LPxTG motif and of a 39-residue signal peptide.   
In the genome comparison the sar5 showed similarities less than 27% with 
CDSs in four of the five genomes used for the comparison. However, it was 
100% similar with a protein from GBS 2603V/R. This is in agreement with 
the result of 100% similarity obtained between protein alignment of the 
CDS-1223 from GMFR293 with hypothetical proteins of 2603V/R, and 95% 
with the BPS protein (same R5) from GBS strain Compton R.   
Since our results from strain 2603V/R were different regarding sar5 from 
those published previously, we also retested this strain for R3 expression by 
immunofluorescence. However, the result obtained was unclear due to weak 
fluorescence signals that appeared in just few of the bacterial cells tested, 
while there was not fluorescence from the majority of cells. Thereafter, lack 
of R3 expression was further confirmed by Western blotting using polyclonal 
anti-R3 antibodies. Nevertheless, there is a possibility that strain 2603 V/R 
tested negative for R3 expression because of gene expression failure, which 
is known to occur in GBS
10
. To further clarify the relationship between R3 
and R5 surface display proteins, we cloned the gene encoding the R5 surface 
protein (sar5) behind an inducible promoter on plasmids pET15. The 
resulting plasmid (pET15sar5) was introduced into E. coli BL21 cell and the 
strains containing the plasmid we streaked on agar plates containing the 
IPTG inducer. However, the E. coli BL21 cells transformants were negative 
when tested for R3 expression by immunofluorescence microscopy. 
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5 DISCUSION  
 
The elucidation of the genes encoding the proteins R3, Z1 and Z2 is 
important since they could have a potential role in GBS serotyping and as 
vaccine candidates. In this study, we identified candidate genes (CGs) for the 
R3, Z1 and Z2 GBS surface exposed proteins, through the sequencing of the 
genome of the strains GMFR293 known to express R3, Z1 and Z2, and 
CMFR30 known to express the Z1 proteins, followed by the sequence 
analysis of their genomes by the use of in silico tools. 
First, we used two different NGS platforms to obtain two complete GBS 
genome sequences. Strain GMFR293 was sequenced through 454 
pyrosequencing, and strain CMFR30 was sequenced by Pacific Biosciences 
(PacBio) technology. To obtain a complete genome for strain GMFR293, the 
genome assembly was assisted by optical mapping and alignments to its 
closest reference genome. Together these approaches led to a complete draft 
genome, although with few regions that need experimental verification. 
It is known that NGS technologies are developing very rapidly in terms of 
sequence output and cost reduction, which allows that draft genome 
sequences can be obtained easily and at low cost
109
. However, within these 
NGS technologies, each platform presents their respective advantages and 
disadvantages. The PacBio platform has been reported to have benefits like 
the highest N50, 99.99 % accuracy, and to produce fewest contigs. In 
addition, it has a relatively low cost per run, which may benefit studies that 
require only few samples to be sequenced. In terms of systemic error, PacBio 
has high error rates, but through the use of circular consensus reads, and 
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because errors are randomly distributed, the error rates are strongly reduced. 
In contrast, 454 have low error rates, but the errors are positionally 
increasing distally, with guanine-cytosine (GC) content, or with 
homopolymers 
110; 111
. Our results showed that although 454 pyrosequencing 
might be a good choice to obtain a genome draft assembly, this technology 
led to many contigs, increasing both the likelihood of errors in the assembled 
genome and the effort needed to obtain a closed genome. In comparison, 
assembly of PacBio sequence reads led to a single contig, obtaining a 
complete CMFR30 genome. We conclude that less effort was needed to get a 
complete draft genome using PacBio compared with the 454 pyrosequencing 
method. However, both methods allowed obtaining the whole GBS genome 
sequences, and their availability allowed the identification of putative 
candidate genes coding for R3, Z1 and Z2 proteins.   
An interesting question is to what degree analysis of draft genomes as 
compared to complete genomes, could result in introduction of errors from 
the sequencing and/or assembly process. Finished data of the highest quality 
is the most desirable state for a genome sequence, but draft quality sequence 
can provide a powerful resource for many genomic studies. In this study, we 
used the GMFR293 draft genome (closed complete genome but with few 
regions that need experimental verification), since we believe that they did 
not influence negatively on the identification of candidate genes, because 
even if there were errors in the sequencing and/or assembly process like lack 
of contig order, most genes were represented in the draft sequence. In 
addition, the GBS draft sequences also provided important information such 
as a comprehensive estimate of the number of genes in the GMFR293 and 
CMFR30 genomes and their classifications. The limitations for using a draft 
genome in genomic analysis has been observed more when using a draft 
sequence as a reference in comparative studies
112
. It could be one of the 
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reasons why the GBS genome comparison approach in this study was less 
successful for the identification of candidate genes than targeted search for 
specific characteristics of the proteins in question. However, the results from 
the genome comparisons increased our knowledge about special features of 
our sequences compared with other GBS genomes, and thereby this approach 
supported the identification of candidate genes.   
Due to a few uncertain regions the GMFR293 draft genome needs to  be 
experimentally verified for this genome can be considered a finished 
genome. 
Second, this work describes the methodological model that we proposed for 
identification of CGs for the R3, Z1 and Z2 streptococcal surface-exposed 
proteins. The criteria used for selecting the CGs were based on previous 
knowledge about some characteristics of the R3, Z1 and Z2 proteins. The 
rationale for candidate gene selection was based on the following criteria: (a) 
CDSs encoding proteins with a MW higher than 50 kDa. This criterion was 
based in the assumption that R3, Z1 and Z2 are high molecular weight 
proteins, according to results obtained from Western blotting in previous 
studies. (b) CDSs with predicted functional annotations as membrane 
associated, surface associated or hypothetical proteins. This criterion was 
chosen from the knowledge that genes encoding the proteins of interest have 
not been previously identified. Therefore, these proteins can be encoded by 
CDSs without known function, or CDSs classified as membrane or surface 
associated proteins without any putative name or function. (C) CDSs 
encoding proteins predicted as potential surface located or secreted. This 
criterion was based on the knowledge of surface exposition of R3, Z1 and Z2 
proteins from their detection by immunological test. This criterion allowed 
us to characterize each CDS in the GMFR293 and CMFR30 genomes, 
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according to its surface exposition potential. It also permitted us to identify 
those CDSs with common features to other GBS surface proteins previously 
identified, which were selected as potential CGs for the R3, Z1 and Z2 
proteins. This methodology allowed us to select the group of potential 
candidate genes.   
Computational approaches for sequence analysis obtained from the 
sequencing processes and their annotation were used to identify CGs. 
Automated annotation of the draft genomes of GMFR293 and CMFR30 
provided valuable preliminary information about their genomes. However, 
annotations from both genomes should preferably be curated manually. 
Approximately 19% of the complete genomes were assigned as hypothetical, 
uncharacterized or putative proteins. Some of the CDSs were specific for 
GMFR293 and CMFR30. It has been reported that hypothetical genes and 
genes with unknown function represent the vast majority of the dispensable 
GBS genome. Our findings are similar to results reported for other bacterial 
genomes including GBS, where around 20% of the predicted CDSs did not 
match any database entries, and an additional 15 to 20% CDSs were similar 
to genes with unknown function, many of them belonging to the dispensable 
genome 
113; 114
. This shows that in spite of the increasing number of 
sequenced genomes, the assignment of function to a sequence remains in 
many cases a challenge, since this will require laboratory experiments which 
are complicated, time consuming and expensive.  Several of the hypothetical 
proteins annotated in the GMFR293 and CMFR30 genomes belonged to 
strain specific gene clusters. They were identified through genome 
comparison used in this study to assist the selection of CGs.   
Based on genome comparison analyses, we concluded that the genes 
encoding R3, Z1 and Z2 most probably did not belong to the group of “strain 
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unique genes” from the disposable genome. This conclusion was based on 
the observation that none of these genes fulfilled the criteria defined for CGs 
for the R3, Z1 and Z2 proteins. If these proteins were not encoded by genes 
of the disposable genome, we had to search among genes of the core 
genome. it has been reported that some proteins could be encoded in the 
genome without detectable expression.  This fact raises the possibility that 
one or more of the GBS genomes used in the comparison (A909, 515, 2603 
V/R and NEM316) could have the gene, in spite of being serotyped as 
negative for the expression of the R3, Z1 and Z2 proteins. In fact, previous 
research indicates that bacterial genes may not always be expressed, or be 
expressed in quantities insufficient for detection of the gene product 
61
.  For 
instance, GBS strains can possess an alpha-like-protein, even if the protein is 
not expressed on the bacterial surface 
45
. This has been reported for R3, 
where strains previously tested and found to be negative for the expression of 
R3, later were found to produce antigen at low level
24
. However, the 
mechanism behind this has not been reported. This result suggested that 
genome comparison might not be the most suitable method to identify CGs 
for these three GBS proteins, and therefore needs to be complemented with 
other approaches. 
In an attempt to reduce the number of candidate genes, molecular weight 
filtering criteria were applied. However, the molecular weight calculated for 
each of the GBS CDSs did not correspond with the expected MWs estimated 
from previous experiments with the R3, Z1 and Z2 proteins. None of the 
CDSs in GMFR293 and CMFR30 had a molecular weight as high as that 
expected for the Z1 protein. This finding could suggest that the molecular 
weight of at least the Z1 protein, previously estimated to be higher than 250 
kDa had been overestimated. If so, a similar molecular weight 
overestimation could have been done for the R3 and Z2 proteins molecular 
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weights as well. The previous estimates of the molecular weights of the three 
proteins were obtained through Western blotting experiments which showed 
multiple bands 
11
. It is, however, known that the analysis of a protein can be 
difficult if multiple bands appear on the blot.  There are several possible 
reasons that could explain this kind of pattern. Multiple bands could be due 
to technical artefacts or could represent true variants of the protein of 
interest, like for instance repeats, which has been reported for other GBS 
surface proteins. Usually, higher molecular weight bands than the real 
molecular weight of the target protein may be seen when there is presence of 
unresolved multimers (protein complexes), or when the target protein is 
postranslationally modified (PTM). 
A similar pattern was reported in the identification of the Srr-2 GBS surface 
protein
115
, where a band was detected at >250 kDa, and the real molecular 
weight determined was 125 kDa.  Several smaller molecular mass bands 
appeared also in the gel. The real Srr-2 protein molecular weight was 
resolved by adding urea (9M) to the buffer. This suggested that the protein 
could exist as a dimer in the absence of strongly denaturing conditions. 
Abnormal migration could also be attributed to the highly repetitive nature of 
the protein. Posttranslational modifications were thought to occur only rarely 
in bacteria. However, mass spectrometry (MS)-based proteomics has shown 
that prokaryotes are capable of modifying proteins with an extensive array of 
posttranslational modifications, and that these may have a profound 
influence on bacterial physiology and virulence
116
, as shown for protein 
phosphorylation in Streptococcus pneumoniae
117
. Based on in silico analyses 
in this study, we conclude that the molecular weights for the R3, Z1 and Z2 
proteins is uncertain and that further studies should be done in order to 
clarify this aspect. However, based on the characteristics previously reported 
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regarding molecular weight for these proteins together with the results 
obtained after characterization of Mws of CDSs of the two genomes, as well 
as the considerations mentioned above, we chose to define a filter for 
molecular weight for CGs for R3, Z1 and Z2 higher than 50 kDa.  
The R3, Z1 and Z2 proteins were previously reported to be surface-exposed 
proteins
11
. Our use of in silico methods permitted the identification of CGs 
with potential of surface exposition. Proteins of Gram-positive bacteria 
destined for transport across the cytoplasmic membrane, frequently contain a 
hydrophobic N-terminal signal sequence. The approach described here 
provides an approximation to potential surface-exposed proteins in 
GMFR293 and CMFR30. Any of the identified CGs could be the genes 
encoding R3, Z1 and Z2. However, it is also important to be aware that not 
all membrane associated proteins have the structural elements used for 
identification by in silico analyses in this study. Some GBS surface proteins 
reported previously have been identified as having atypical structure 
characteristics, which basically means that exceptions could occur. For 
instance, proteins of Gram-positive bacteria destined for transport across the 
cytoplasmic membrane, frequently contain a hydrophobic N-terminal signal 
sequence
118
. Peculiarly, a number of secreted streptococcal proteins lack 
apparent secretion signal sequences
119
; thus the mechanism by which these 
proteins are transported to the bacterial cell surface is yet to be elucidated. 
A further characterization of the R3, Z1 and Z2 proteins using for instance 
proteomics approaches could contribute to a more suitable prioritization to 
target a more limited group of CGs, or even to identify some CDSs which 
were discarded by the filters used in this study. In fact, similar studies 
combining proteomics and in silico prediction methods have been reported 
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for the identification of vaccine candidate genes for Group A Streptococcus 
(GAS)
120
, Streptococcus pyogenes
121
 and other bacterial genera
122
.  
In addition, based on CG prioritization by in silico analysis of the CDSs in 
the GMFR293 genome, we found that the gene encoding to R5 appears to be 
a strong CG for R3 (CDS-1223). From the beginning of the project, the 
possibility that R3 could be identical to R5 was one of the formulated 
hypotheses. During this work several analyses were done to attempt to 
clarify the R3-R5 relationship. The negative results by immunofluorescence 
testing for R3 expression from strain 2603V/R by Western blotting, and from 
E. coli BL21 cells transformants could indicate that they are different 
proteins. However, as discussed above, low level expression of the protein 
below the detection limit could be an explanation for the negatives results. In 
addition, there may be several other ways to explain the negative result for 
R3 expression, by immunofluorescence testing of E. coli BL21 cells 
transformants. First, a not recombinant protein may have been produced by 
the transformed E. coli LB 21 cells, or that E. coli LB21 cells had been 
transformed, but they did not express the R3 protein.  Second, the 
recombinant protein may have been located intracellularly.  Finally, the 
protein may not have been secreted. Unfortunately, time restrictions did not 
permit further testing of these possibilities Future studies along these lines 
are therefore recommended. 
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6 CONCLUSIONS 
 
The work described in this thesis is the first attempt to identify the genes 
encoding the R3, Z1 and Z2 surface exposed protein of GBS. It was done 
through the sequencing of two GBS genomes and the analysis of their 
genome sequences. From the results obtained in this thesis, we conclude the 
following aspects: 
The GBS strains GMFR293 and CMFR30 were sequenced and assembled 
into complete genomes, annotated and characterized. The availability of 
these strains allowed making the analysis needed for selection of the 
candidate genes for R3, Z1 and Z2 proteins. However, to obtain finished 
genomes, uncertain regions of the draft genomes need to be verified 
experimentally.   
Genome comparison analysis were not a suitable approach to select 
candidates genes coding for R3, Z1 and Z2 surface exposed proteins of GBS. 
However, the comparison of GMFR293 and CMFR30 against other GBS 
genomes allowed identification of the strain-specific genes from both 
Zimbabwean strains. 
The genome analysis using in silico tools was a rapid and inexpensive 
approach to target CGs for the R3, Z1 and Z2 GBS surface proteins.  
Additionally, a relevant conclusion from this work is the demonstration that 
a comprehensive characterization in silico of surface-exposed proteins can 
lead to candidate gene discovery of surface exposed proteins. 
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Finally, 51 CGs were chosen as CGs for R3, Z1 and Z2 in the GMFR293, 
and 32 CDSs were chosen as CGs for Z1 in GMFR30 genome. Among them, 
there were CDSs annotated as hypothetical protein with putative function, 
and some with predicted function. The results presented in this study 
represents an interesting first stage in the way for discovering the genes 
encoding the R3, Z1 and Z2 GBS surface exposed proteins. However, CGs 
identified by in silico analyses need to be tested further via experimental 
analyses for validation of the results. Further outcomes may be obtained if 
more information about the proteins becomes available in future.   
The relationship between the R5 and R3 GBS proteins could not be clarified 
in this study, in spite of the experiments done. However, the gene coding for 
the R5 protein appears as one of the potential CGs for the R3 and Z2 surface 
exposed proteins by in silico analysis. Unfortunately, time restrictions did 
not permit further testing. 
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8 Appendix  A. Uncertain regions detected 
due to differences between the optical 
restriction map and the in silico restriction 
map patterns. 
 
No GMFR293 
 in silico 
fragment 
number 
GMFR293 
 in silico 
fragment 
size 
GMFR293 
Optical Map 
matching 
fragment 
GMFR293 
Optical Map 
fragment size 
1 5 12.948 4 12.856 
2 6 5.873 5 6.641 
3 7 1.296 no match 0 
4 8 0.987 no match 0 
5 9 1.694 no match 0 
6 10 1.337 no match 0 
7 11 6.326 8 7.008 
8 12 0.471 no match 0 
9 13 1.492 no match 0 
10 23 3.356 18 3.574 
11 24 12.163 19 15.024 
13 28 26.121 22 25.702 
15 32 0.207 no match 0 
16 33 0.941 no match 0 
17 34 8.38 no match 0 
18 35 16.994 no match 0 
19 38 12.584 29 13.369 
20 39 0.717 no match 0 
21 40 0.416 no match 0 
22 42 19.395 31 19.049 
23 50 7.387 38 7.434 
24 56 4.824 43 5.104 
25 57 1.433 no match 0 
26 58 1.588 no match 0 
95 
 
27 59 2.923 45 3.189 
28 61 4.385 47 4.494 
29 62 1.934 no match 0 
30 63 0.001G no match 0 
31 64 0.002 no match 0 
32 65 0.001G no match 0 
33 66 0.397 no match 0 
35 73 4.886 54 5.101 
36 74 4.871 55 5.532 
37 79 5.516 no match 0 
40 86 13.728 64 14.085 
41 91 4.631 68 5.437 
42 111 12.973 87 12.28 
43 126 13.127 101 13.797 
44 133 6.892 107 6.979 
45 134 1.583 no match 0 
47 136 3.593 109 3.719 
48 137 0.123 no match 0 
49 148 19.42 120 18.805 
50 163 6.049 134 6.603 
59 198 11.949 164 12.042 
61 202 0.403 no match 0 
63 209 0.122 no match 0 
65 228 1.679 no match 0 
66 229 396 no match 0 
67 230 8972 no match 0 
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9 Appendix B.  Uncertain regions identified 
from the GBS GMFR293 genome assembly.  
 
No 
GMFR293  
Frag. No  
Size 
(Kb) Start End 
Size 
(bp) 
No 
match 
DRP  
1 
Size 
Error %  
DRP 
2 
Diff. size 
Ref. gen 
1 63 0.001 392420 392421 1 x 
  
x 
 2 65 0.001 392423 392424 1 x 
  
x 
 3 64 0.002 392421 392423 2 x 
  
x 
 4 137 0.123 1113140 1113263 123 x 
   
X 
5 66 0.397 392424 392821 397 x 
  
x 
 6 33 0.941 224317 225258 941 x 
  
x 
 7 83 1.379 551674 553053 1379 
 
x x 
  8 58 1.588 373160 374748 1588 x 
  
x 
 9 228 1.679 1978622 1980301 1679 x 
  
x 
 10 62 1.934 390486 392420 1934 x 
  
x 
 11 183 9.027 1520311 1522769 2458 
 
x x 
  12 167 2.579 1368071 1370650 2579 
 
x x 
  13 59 2.923 374748 377671 2923 
 
x 
 
x 
 14 135 3.188 1106359 1109547 3188 
 
x x 
  15 23 3.356 153085 156441 3356 
 
x 
  
X 
16 61 4.385 386101 390486 4385 
 
x 
 
x 
 17 91 4.631 725427 730058 4631 
 
x x x 
 18 74 4.871 506746 511617 4871 
 
x x 
  19 6 5.873 59432 65305 5873 
 
x x 
  20 11 6.326 70619 76945 6326 
 
x x 
  21 189 6.404 1563347 1569751 6404 
 
x x 
  22 34 8.38 225258 233638 8380 x 
  
x 
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23 198 11.949 1652179 1664128 11949 
 
x 
 
x 
 24 24 12.163 156441 168604 12163 
 
x x 
 
x 
25 5 12.948 46484 59432 12948 
 
x 
  
x 
26 86 13.728 593344 607072 13728 
 
x 
 
x 
 27 35 16.994 233638 250632 16994 x 
  
x 
 28 227 17.95 1960672 1978622 17950 
 
x 
  
x 
29 68 28.186 394379 422565 28186 
 
x 
  
x 
 
*(DRP 1: different restriction pattern compared to that of the optical map, 
DRP 2: different restriction pattern compared to that of the optical map of 
reference genomes). 
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10 Appendix C. GBS CMFR30 strain specific 
genes.  
 
CDs Annotation MW 
(kDa) 
Topology GEIs 
83 FIG01114815: hypothetical protein 26 Inside  
295 Hypothetical protein 4.1 outside  
421 Hypothetical protein 3.8 TM I 
602 Hypothetical protein 6.2 outside  
606 Conserved hypothetical protein - phage 
associated 
7.6 TM  
608 Hypothetical protein 8.1 outside  
613 Hypothetical protein 9.1 Inside III 
616 hypothetical protein 5.8 TM III 
620 Hypothetical protein 4.2 TM  
716 Hypothetical protein 4.9 outside  
734 Hypothetical protein 4 TM IV 
778 Hypothetical protein 4.3 TM  
782 Hypothetical protein 4 TM  
812 Hypothetical protein 4.2 outside  
939 Conserved hypothetical protein 4.6 outside  
941 Hypothetical protein 11.7 outside  
1146 Hypothetical protein 8.2 outside  
1455 Hypothetical protein 4.7 TM  
1605 Hypothetical protein 8.8 outside  
1665 Hypothetical protein 7.3 TM  
1666 Hypothetical protein 7.2 TM  
1668 Hypothetical protein 13.7 Inside  
1669 Hypothetical protein 11.6 outside  
1670 Hypothetical protein 4.2 outside  
1796 Hypothetical protein 4.2 TM  
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11 Appendix D. Candidate genes for the R3, 
Z1 and Z2 surface exposed proteins in the 
GBS GMFR293 genome. 
 
No CDS MW 
(Kda) 
Topology Signal 
peptide 
YSIRK LPxTG Lipo- 
protein 
annotation 
1 137 72.41 TM x  x  Hypothetical protein 
2 189 61.05 TM x  x x Hypothetical protein 
3 298 54.41 TM     Hypothetical protein 
SPy1643 
4 384 56.34 outside x x   Cell wall surface 
anchor family protein 
5 415 118.16 TM     Cell surface protein 
6 431 91.30 TM     Surface protein Rib 
7 532 53.13 outside     Hypothetical protein 
8 601 71.83 outside     Membrane proteins 
related to 
metalloendopeptidases 
9 651 78.40 outside     Hypothetical protein 
10 747 54.38 TM x    Cell wall surface 
anchor family protein 
11 758 85.54 TM    x Late competence 
protein ComEC, DNA 
transport 
12 965 54.49 TM    x Carbon starvation 
protein A 
13 991 52.03 TM x    Putative secretion 
accessory protein 
EsaA/YueB 
14 1039 74.35 TM   x  Kup system potassium 
uptake protein 
15 1154 94.16 TM x    Conserved domain 
protein 
16 1163 139.74 TM x x   Pullulanase  
17 1185 119.70 outside x    C5a peptidase  
18 1186 53.14 outside     Hypothetical protein 
19 1223 105.62 TM x x x  Hypothetical protein 
20 1229 66.24 TM    x Lipid A export ATP-
binding/permease 
protein MsbA 
21 1230 64.89 TM   x  Lipid A export ATP-
binding/permease 
protein MsbA 
100 
 
22 1242 60.12 TM x x   Surface antigen-related 
protein 
23 1282 60.32 TM     Membrane protein 
involved in the export 
of O-antigen, teichoic 
acid lipoteichoic acids 
24 1299 73.49 TM x    Cell wall surface 
anchor family protein 
 
25 1300 101.01 TM x    Cell wall surface 
anchor family protein, 
FPXTG motif 
26 1304 52.84 TM   x  Membrane protein 
involved in the export 
of O-antigen, teichoic 
acid lipoteichoic acids 
27 1305 51.73 TM   x x Membrane protein, 
putative 
28 1311 66.65 TM x   x Lipoprotein involved in 
the synthesis of group 
B streptococcal 
carboyhdrate antigen 
29 1357 79.05 TM x  x  Glutamine ABC 
transporter, glutamine-
binding 
protein/permease 
protein 
30 1365 74.58 TM x   x Amidase family protein 
31 1376 64.35 TM     Membrane protein, 
putative 
32 1434 83.13 TM     Hypothetical protein 
33 1435 50.28 outside     Hypothetical protein 
34 1469 52.61 TM    x Potassium uptake 
protein TrkH 
35 1501 57.51 TM     Transmembrane 
histidine kinase CsrS 
36 1734 52.71 outside     Hypothetical protein 
37 1761 52.15 TM    x PTS system, galactose-
specific IIC component  
38 1766 53.32 TM x    Streptococcal histidine 
triad protein 
39 1779 80.77 TM x    Membrane protein, 
putative 
40 1780 93.31 outside     Hypothetical protein 
41 1786 53.37 TM     Hypothetical protein 
42 1808 77.75 TM    x PTS system, maltose 
101 
 
and glucose-specific IIC 
component 
43 1837 74.74 TM    x Membrane protein, 
putative 
44 1854 94.20 TM x    Hypothetical protein 
45 1855 81.69 TM x   x Conserved domain 
protein 
46 1899 172.29 TM x x   Serine endopeptidase 
ScpC 
47 1914 61.03 TM     Hypothetical protein 
48 1934 59.33 TM    x Competence-induced 
protein Ccs4 
49 1960 54.76 outside     Hypothetical protein 
50 1979 96.67 TM   x  Membrane protein, 
putative 
51 1989 74.56 TM    x Phosphoesterase, DHH 
family protein 
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12 Appendix E.  Candidate genes for 
Z1surface exposed protein obtained from 
GBS CMFR30 genome. 
 
CG 
No 
CDS MW 
(Kda) 
Topology Signal 
Peptide 
YSIRK LPxTG Lipo- 
protein 
Annotation 
1 112 102.1 outside  x x  Surface protein Rib 
2 128 105.6 TM   x  Cell surface protein 
3 133 80.1 TM   x  C5a peptidase  
4 159 52.4 outside x x x x Cell wall surface anchor 
family protein 
5 305 54.5 Inside     Hypothetical protein 
6 399 55.2 TM x   x Oligopeptide ABC 
transporter, 
periplasmic 
oligopeptide-binding 
protein OppA  
7 410 62.8 TM x    Hypothetical protein 
8 594 66.1 TM    x Phosphoesterase, DHH 
family protein 
9 628 84.7 outside   x  Membrane protein, 
putative 
10 671 51.4 TM    x Competence-induced 
protein Ccs4 
11 690 54.7 TM     Hypothetical protein 
12 694 73.2 TM   x  Putative peptidoglycan 
linked protein (LPXTG 
motif) 
13 702 157.2 TM x x x  Serine endopeptidase 
ScpC 
14 801 80.1 TM x  x  Cyclic-nucleotide-
phosphodiesterase  
15 944 63 TM     Hypothetical protein 
16 1025 88.2 TM    x Pyruvate,phosphate 
dikinase  
17 1071 50.2 TM     Transmembrane 
histidine kinase CsrS 
18 1140 72 TM     Hypothetical protein 
19 1191 53.1 TM x    SLH, S-layer homology 
domain W 
20 1196 54.9 TM     Membrane protein, 
putative 
21 1207 68 TM x  x x Amidase family protein 
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22 1271 89.7 TM x  x  Cell wall surface anchor 
family protein, FPXTG 
motif 
23 1272 68.3 outside x  x  Cell wall surface anchor 
family protein 
24 1289 54.5 outside     Membrane protein 
involved in the export 
of O-antigen, teichoic 
acid lipoteichoic acids 
 
25 1328 54.5 outside x x x  Surface antigen-related 
protein 
26 1424 85.5 TM x    Conserved domain 
protein 
27 1593 100.6 TM x    Putative secretion 
accessory protein 
EsaA/YueB 
28 1770 81.6 TM     Hypothetical protein 
29 1771 72.6 outside x    Membrane protein, 
putative 
30 1957 88.6 outside     Lactocepin (Cell wall-
associated serine 
proteinase)  
31 1981 90.3 outside   x  Cell wall surface anchor 
family protein, FPXTG 
motif 
32 1985 55.5 outside x  x  Cell wall surface anchor 
family protein 
 
